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Abstract 
 
The mechanisms that regulate the differentiation of stem cells (SCs) into cardiomyocytes are 
still unclear and the role of endogenous molecules on this process remains unexplored. One 
such molecule is the bioactive phospholipid lysophosphatidic acid (LPA) which accumulates 
in the myocardium following acute infarction and exerts multiple biological functions, 
including the regulation of cell growth and differentiation as well as cell survival (Tigyi et al., 
2003; Sengupta, et al., 2004). Experiments were therefore carried out in this thesis to reveal 
whether LPA can induce the differentiation of stem cells into cardiomyocytes and to identify 
the signalling mechanisms that mediate this effect.  
 
All experiments were carried out in the mouse P19 carcinoma stem cell line. Treatments with 
LPA in the absence and presence of various pharmacological compounds were conducted in 
embryoid bodies (EBs) formed from the P19 cells in sterile Petri dishes over 4 days. The EBs 
were subsequently transferred into 6-well cell culture plates and cultured for specific time 
points. Lysates were generated and subjected to western blotting for expression of cardiac-
specific myosin light chain -1v (MLC-1v). To look at the expression of LPA receptors 
(LPAR1-LPAR5) experiments were carried out by RT-PCR using specific primers for each 
LPA receptor and the role of the latter in mediated responses to LPA were examined in the 
presence of the LPAR 1/3 antagonist, Ki16425, or the LPAR 4 receptor blocker suramin. In 
addition, experiments were carried out investigating the role of Gi and specific signalling 
pathways that may be involved in the differentiation of P19 cells. These were carried out 
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using potent inhibitors/antagonists of Gi inhibitor (Pertussis toxin), PI3K inhibitor 
(LY294002), Akt inhibitor (Akt inhibitor XIII), PKC inhibitor (Bisindolylmaleimide I BIM-I), 
ROCK inhibitor (Y-27632), p38-MAPK inhibitor (SB203580) and ERK1/2 inhibitor (PD98059). 
Further experiments were carried out to establish whether the presence of LPA results in the 
phosphorylation of the targeted kinases. These studies were however limited to Akt, p38 
MAPK and ERK1/2. 
 
Incubation of cells with LPA resulted in the differentiation of P19 cells into cardiomyocytes as 
reflected by the induction of MLC-1v. The latter increased significantly above basal in a time-
dependent manner, reaching a maximum 10 days after plating EBs in 6-well plates. The 
induction of MLC-1v was more pronounced in cells incubated with 5 µM LPA at 6 days but 
showed little concentration differences at day 12. RT-PCR analysis confirmed the expression 
of LPA receptors 1 to 4 but not 5. Pre-incubating cells with suramin and Ki16425 
concentration-dependently inhibited MLC-1v expression with 0.05 mg/ml and 10 M 
respectively, virtually abolishing the expression of MLC-1v. Additionally, inhibitors of 
LPAR1/3 and LPAR4 receptors and all the signalling inhibitors except SB203580 abolished 
the phosphorylation of ERK1/2. Similarly, p38 MAPK activation was completely abolished by 
LPAR1/3 and LPAR4 receptor antagonists, Interestingly, only LY294002 (5 M) and Y27632 
(10 M) abolished the LPA induced activation of p38 MAPK while SB203580, BIM-I, Akt 
inhibitor XIII and PD95080 caused no significant changes to the phosphorylation of p38 
MAPK. 
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In conclusion, the studies carried out in this thesis have shown that LPA can induce P19 
stem cells to differentiate into cardiomyocytes and they are linked to the well characterised 
LPA receptors (LPAR1/3 and 4). These receptors are coupled to downstream signalling 
pathways of which those involving the ROCK, PI3K, PKC and/or Akt may be critical, and may 
converge on ERK1/2. Inhibition of any of these pathways has the potential to suppress 
differentiation. In contrast, signalling leading to p38 activation may potentially suppress 
differentiation but this needs further clarification.  
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Introduction 
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1.1 Coronary heart disease 
Cardiovascular diseases such as coronary artery disease or atherosclerosis remain the 
leading cause of mortality all over the world. The primary risk factors that lead to the 
impairment of the heart and vascular systems are obesity, diabetes mellitus, smoking, and 
additionally age, gender, sedentary lifestyle and heredity (Brekke et al., 2014; Kurian et al., 
2007). The physiological and biochemical changes induced by these factors may lead to 
myocardial infarction precipitated by myocardial ischemia following the development of 
coronary artery disease or atherosclerosis. 
1.1.1 Pathophysiology of atherosclerosis  
Atherosclerosis is characterised by plaque formation and obstruction of coronary arteries. 
Atheroma formation results from the subendothelial accumulation of lipids, mainly 
triglycerides and low-density lipoprotein (LDL) in the arterial walls along with circulating 
monocytes that lead to the formation of fatty streaks. Further, smooth muscle cells migrate 
and proliferate in the intimae in response to chemokines leading to neointima formation. 
This continued process of lipid accumulation and cellular changes can lead to stenosis of 
the vessels. The atheromatous tissues can also undergo rupture with platelet plugs, leading 
to occlusion of the coronary arteries. This leads to myocardial ischemia and subsequently 
myocardial infarction (MI). 
1.1.2 Myocardial Infarction (MI) 
Myocardial infarction is a major cause of death arising from an atherosclerotic plaque. It is 
due to reduced blood and oxygen supply to the heart muscles leading to necrosis of the 
portion of myocardium that is poorly perfused with blood. Clinically, MI is defined by 
persistent ST segment elevation on an electrocardiograph, which is characteristic of the 
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ischemic symptoms. The major causes are occlusions of the blood vessels due to atheroma 
formation subsequently leading to narrowing and hardening of the coronary arteries and 
aortic stenosis. Other causes include sudden immense need of blood supply to the 
heart as in the case of haemorrhage, shock and severe physical exertion. The other major 
risk factors which can lead to MI are diabetes mellitus, hypertension, hyperlipidaemia, 
smoking, gender (particularly male) and familial. It is observed that these risk factors double 
the incidents of MI (Ross et al., 1999). 
1.1.3 Treatments 
The preliminary strategies for treating coronary artery disease are to restore normal blood 
flow through the coronary arteries and to recover the myocardium (Anderson et al., 2007; 
Krumholz et al., 2008). This can be achieved using pharmacological interventions, for 
instance, by administration of antiplatelet agents such as aspirin. Aspirin inhibits the 
cyclooxygenase pathway (COX1) irreversibly and thus prevents the formation of 
thromboxane A2 and the activation of platelet aggregation. Fibrinolytic drugs like 
streptokinase and reteplase stimulate the production of plasminogen that disintegrate 
fibrin. Statins such as pravastatin and atorvastatin are also recommended for patients with 
MI. These statins competitively inhibits the HMG CoA reductase, the rate-limiting 
enzyme for cholesterol biosynthesis. In doing so, these drugs reduce the production of 
the very low-density lipoprotein (VLDL), the precursors for low-density lipoprotein 
(LDL). As a result, they cause increased LDL receptor expression and lead to a 
decrease in the level of LDL in the circulation (Cannon et al., 2004). However, none of 
these pharmacological interventions actually cures the disease state but rather regulate the 
consequence and symptoms of the disease. 
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An alternative to pharmacological intervention is heart transplant especially where the heart 
is infarcted resulting in a high risk of mortality. This approach, by its nature, also has several 
limitations including cost and immune rejection as well as limited donor availability due to 
increased young population with heart disease along with an increasing population of an 
elderly group with end stage heart failure. Thus, there is a concerted effort to develop 
strategies that will overcome these hurdles and result in the successful regeneration of the 
myocardium. In this regard, stem cell therapy has become very prominent as a potential tool 
in translational medicine for regenerating the human heart.  
1.2 Stem cells (SCs)  
Stem cells (SCs) are unspecialised cells capable of undergoing self-renewal without going 
into senescence but can be induced to become specialised cells (Evans et al., 1981). 
Thus, SCs have the capacity to maintain and repair tissues within the body. Depending 
on the potency to differentiate into specialised cells, stem cells are categorized into 
totipotent, pluripotent, multipotent and oligopotent. 
  
Totipotent cells derived from the early divisions of the zygote have the potential to give rise 
to virtually all cells of the body. Pluripotent cells are primarily present in the inner cell mass 
at the blastocyst stage of the embryo and have the capacity to differentiate into cells and 
tissues of the three primary germ layers namely ectoderm, mesoderm, and endoderm. 
Multipotent cells are characterised by the potential to differentiate into several but  l im i ted 
cell types as in the case of haematopoietic stem cells, which can give rise to different 
blood cells. Unipotent stem cells can give rise to only a specific cell lineage. 
27 
 
 
Depending on their origin, stem cells can be divided into two major groups, namely adult or 
somatic stem cell and embryonic stem cells (ESCs). 
1.2.1 Stem cell types 
1.2.1.1 Adult stem cells or Tissue-restricted stem cells 
Adult stem cells (ASCs) are multipotent and maintain tissue repair that restore dying cells in 
tissues.  Adult stem cells have been isolated from various organs including blood, bone 
marrow, muscle, skin, liver, adipose tissue, heart, brain (Laugwitz et al., 2008; Mackay et 
al., 1998; Schmelzer et al., 2007). Hematopoietic stem cells, mesenchymal stem cells 
(MSCs), umbilical cord stem cells and olfactory mucosal stem cells are few examples of 
ASCs. Studies have shown the potential of ASCs to differentiate into other types of cells. 
For example Human MSCs could be differentiated into smooth muscle cells (Bajpai et al., 
2012), to osteoblasts (Dieudonne et al., 2013) and to cardiomyocytes (Toma et al., 2002).  
1.2.1.2 Embryonic stem cells (ESCs) 
Embryonic stem cells are pluripotent stem cells derived from the inner cell mass of pre-
implanted blastocyst (3-5 day) comprising of 3 structural components namely trophoblast, 
blastocoel and inner cell mass (Evans et al., 1981; Martin, 1981). Trophoblasts are the 
cells covering the blastocyst, which gives rise to the formation of extra-embryonic 
tissues: placenta and umbilical cord. The hollow cavity is called the blastocoel carrying the 
inner cell mass. Other forms of ESCs are embryonic carcinoma cells (ECCs) derived from 
malignant germ cell tumours called teratocarcinoma (Martin, 1975). Embryonic germ cells 
(EGCs) originate from primordial germ cells (PGCs) in the gonadal ridge. During normal 
embryogenesis PGCs give rise to the germ cells, sperm or egg (Shamblott et al., 1998). 
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Embryonic stem cells being pluripotent have high potential to differentiate into various 
lineages include cardiomyocytes. However, there has been much success achieving this in 
vitro than in vivo especially in relation to translation medicine. One of the limitations with 
ESCs is the fact that they have a tendency to form teratoma in vivo. Moreover, there are 
ethical as well as immunogenicity issues that limit the exploitation of these cells in full. Thus, 
alternative sources of stem cells are required and this has led to the generation of induced 
pluripotent stem cells (iPSCs) which gets around, at least, the ethical and immunogenic 
concerns (Hentze et al., 2009; Ida, 2008). 
1.2.1.3 Induced pluripotent stem cells (iPSCs) 
Induced pluripotent stem cells are derived from non-pluripotent adult somatic cells by 
inducing the expression of specific transcription factors and pluripotency markers specifically 
octamer-binding protein-3/4 (Oct3/4), sex determining region Y-box 2 (Sox2), Kruppel-like 
factor-4 (Klf4) and c-Myc (Takahashi et al., 2006). Alternatively, a combination of Oct4, Sox2, 
Lin28 and Nanog could also be used to induce pluripotency in human cells (Liao et al., 2008; 
Okita et al., 2008). Currently researchers have successfully differentiated iPSCs to neuronal 
cells, astrocytes (Juopperi et al., 2012; Yuan et al., 2013) cardiomyocytes and hepatocytes 
(Di Pasquale et al., 2013; Miki et al., 2013). The most important advantage of iPSC 
technology is that it does not involve ethical issues associated with ESCs, and only requires 
the consent of the patient. In addition, the patient phenotype could be greatly correlated and 
therefore iPSCs could standout better in generating cells for specific disease condition which 
are not possible with ESCs. It is notable that the iPSCs from each individual are typical and 
unique and differ from individuals with the same genetic disorder (Ellis et al., 2011). 
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Presently, there are different methods used to develop iPSCs, which include a non-viral 
integrating vector method, deletion after integration, DNA free methods and chemical 
induction method. A full description of each of these protocols is beyond the scope of this 
thesis but worth pointing out that the non-viral integration method has been developed using 
viral vectors like adenovirus, sendai virus and non-viral vectors like episomal vector/ plasmid 
vectors and expression plasmids. However, among these the sendai viral incorporation has 
been reported to produce high efficiency in generating iPSCs (Zhou et al., 2013). This 
method prevented the incorporation of any of the viral gene into the target and minimised 
mutagenesis and changing the prospective to differentiate the cells (Shi et al., 2008). 
Currently, researchers are focused on increasing the efficiency of the reprogramming 
process and are exploiting techniques such as mRNA and reprogramming proteins to 
produce high efficiency in generating iPSCs when compared to the viral vector method (Zhou 
et al., 2013). Lately, at least one study has reported that the efficiency of reprogramming was 
improved close to 100% by the reduction of the Mbd3, a Nucleosome Remodelling 
Deacetylase complex subunit that is considered to directly interact with Klf4, Oct3/4, Sox2, 
and c-Myc (KOSM) transcription factors (Luo et al., 2013).   
 
Researchers have also discovered chemicals that increase the efficiency in generating 
iPSCs include compounds such as SB431412, PD0325901 and Thiazovivin. These 
compounds increase the reprogramming efficiency and furthermore shorten the time for the 
whole process (Lin et al., 2009). Valproic acid/HDAC inhibitor and 616452/ Transforming 
growth factor  ( TGF- inhibitors have also been shown to increase efficiency, even when 
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Oct4 alone was used to reprogram the cells (Masuda et al., 2013). Another potential 
approach reported, is the use of micro RNA to improve reprogramming efficiency of iPSCs. 
Micro RNAs have also been shown to regulate the differentiation in multiple cell systems and 
after differentiation of ESCs miR-302 has been reported to be down regulated. In addition the 
efficiency of reprogramming was increased when iPSCs were induced with miR-302 along 
with KOSM transcription factors (Anokye-Danso et al., 2012). There are reports suggesting 
that miR-155 acts as an inducer in the differentiation of iPSCs into hematopoietic progenitor 
cells (Vitaloni et al., 2013). Interestingly, another study reports that the generation of iPSCs 
was completely blocked when miR-302/367 were knocked out in human fibroblasts (Zhang et 
al., 2013). 
1.2.2 Stem cell pluripotency 
The regulatory mechanisms that control the maintenance of pluripotency include 
chromatin stability, transcription factors, cell cycles, extracellular signalling molecules and 
micro RNA circuits (Sokol et al., 2011; Tsubouchi et al., 2013; Wan et al., 2013.). In ESCs 
the chromatin is likely to be trimethylated on histone 3 (Lysine 4) and is acetylated on 
histone 4. These areas are more associated with trithorax and the polycomb-group (PcG) 
proteins that regulate pluripotent gene expression, thus maintaining the pluripotency of 
ESCs. Trimethylation of histone 4 at Lysine 27 (inactivation) and its association with PcG 
promotes lineage specific gene expression and thus lineage commitment (Ringrose, 2007). 
Interestingly, transcription factors like Sox2, Nanog, and Oct3/4,  bring about repression 
a t  histone 4 trimethylation. As explained above, stem cells pluripotency is sustained by 
mutual interactions of transcription factors Oct-3/4, Sox2 and Nanog. Oct-3/4 attaches to 
AGTCAAAT octamer sequence of the target gene and belongs to a POU family of 
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transcription factors.  Oct-3/4 is expressed in the early embryo but is down regulated 
during formation of ectoderm and endoderm (Brehm et al., 1998). In the inner cell mass 
(ICM), Oct-3/4 forms a complex with cdx2 transcription factor to initiate specific lineage 
commitment. Studies also suggest that the levels of Oct-4 is vital as repression of this 
transcription factor initiates differentiation to trophectoderm whereas its over expression 
can lead to extra-embryonic endoderm formation (Niwa et al., 2000). Sox2 is expressed in 
the ICM epiblast and is later confined to neural tube (Avilion et al., 2003). It is a SRY-
related HMG box gene member and its over expression directs stem cells to differentiate 
into neuronal precursors. Oct-4 and Sox2 can regulate pluripotency and gene 
expression by binding to adjacent sites on regions of the promoters of the pluripotent 
genes.  
 
Oct-3/4 and Sox2 are reported to induce the expression of several genes including 
fibroblast growth factor (FGF)-4, undifferentiated embryonic cell transcription factor 1 
(UTF1) and Nanog (Boyer et al., 2005; Yuan et al., 1995). In addition, it is observed that 
at some stage during induction of differentiation there is a down regulation of Oct3/4, 
Sox2 and UTF1. These changes also denote negative regulation caused by Oct-3/4 and 
Sox2 on the expression of UTF1 (Boyer et al., 2005; Nishimoto et al., 1999). Nanog in 
mouse is expressed in ICM and early epiblast but embryo failed to form an epiblast 
when this gene was deficient (Mitsui et al., 2003). Evidence also indicates that Nanog null 
Mouse embryonic stem cells (mESCs) are directed to differentiation in the presence of 
Leukaemia Inhibitory Factor (LIF) but it’s overexpression helps ES cell to self-renew even in 
the absence of LIF (Chambers, 2004). From the above reports, it is suggested that these 3 
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transcription factors have to be jointly synchronized to maintain stem cell self-renewal and 
pluripotency. 
 
Cell cycle is yet another important crucial point that decides cell fate. ESCs at the epiblast 
stage mostly exist in the S1 phase with less G1 phase. This is unlike somatic cells where 
G1 is the predominating phase and determines the fate of cells to proliferate, differentiate, 
senesce or undergo apoptosis (Burdon et al., 2002). ESCs are therefore maintained in their 
self-renewal and pluripotency state due to their maintenance in the S1 rather than the G1 
phase. 
1.2.3 Stem cells for heart diseases 
Numerous studies in human and animal models have demonstrated the potential of 
exploiting stem cells in regenerative medicine and potentially in developing stem cells-
derived cardiomyocytes (Iglesias-Garcia et al., 2013; Pfister et al., 2014). This is 
demonstrated by recent studies reporting transplantation of human embryonic stem cells 
derived cardiomyocytes, (hESC-CM) improved myocardial function in the ischemic heart. 
The above data shows the therapeutic potentials of stem cells in regenerating the infarcted 
heart. 
 
Similarly, other studies have also suggested the role of stem cells in regenerating the 
infarcted myocardium (Caspi et al., 2007). This study in infarcted rat showed that the grafting 
of pre-differentiated hESC-CM improved cardiac functioning and prevented teratoma 
formation. Embryonic stem cells derived cardiomyocytes (ESC-CM) and mesenchymal stem 
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cells derived cardiomyocytes (MSC-CM) have revealed predictable morphology and action 
potential similar to the rhythmic contractions of normal cardiomyocytes (Antonitsis et al., 
2008; Labovsky et al., 2010; Reppel et al., 2005). A recent report has shown that aggregates 
of contracting hESC-CM improved myocardial function in infarcted hearts of rat however; in 
contrast, another study has shown that injection of hESC-CM in rat heart did not show any 
significant improvement in left ventricular function in a chronic myocardial model (Fernandes 
et al., 2010; Moon et al., 2013). Encouragingly though, iPSC-CM have been shown to 
successfully improve myocardial functioning in infarcted rat hearts. The iPSC-CM derived 
from H9c2 cells also appears to induce neovascularisation in the infarcted mouse heart (Miki 
et al., 2012; Singla et al., 2011). 
 
There are several reports of clinical trials with different types of stem cells. The study with 
autologous adipose derived regenerative stem cells improved the left ventricular function of 
patients with no alternative treatment option (Perin et al., 2014). Previous studies conducted 
looking at the role of autologous bone marrow stem cells in acute myocardial infarction 
reported that the condition was significantly improved but the mode of administration and 
dose has to be optimised for reproducibility (Martin-Rendon et al., 2008). In addition, the 
intramyocardial injection of CD34+ cells in phase1 and IIa trials in intractable angina patients 
showed improvement (Losordo et al., 2007). However, the delivery of bone marrow 
mononuclear cells administered through trans endocardial injection did not show 
improvement in patients with chronic heart failure (Perin et al., 2012). In contrast, 
intramyocardial injection of bone marrow stem cells have been shown to improve 
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angiogenesis, exercise time and left ventricular ejection fraction (LVEF) in other trials 
(Briguori et al., 2006; Tse et al., 2007).  
 
Despite some of the current limitations, it is becoming evident that stem cell therapy holds 
promise for regenerative medicine with excellent potential to provide an alternative 
therapeutic approach for the infarcted heart. However, there are still many hurdles to 
overcome, if therapeutic outcomes are to be successful. These obstacles include viability 
and integrity of cells, proper delivery routes, electromechanical integrity, and understanding 
the cellular mechanisms that regulate differentiation (Harding, 2014). 
1.2.4 Mechanisms that regulate the generation of cardiomyocytes from 
stem cells. 
Currently cardiomyocytes could be generated from co-culture with mouse visceral Endoderm 
like cells (END-2), through embryoid body (EB) formation, with growth and intrinsic factors as 
well as high density monolayer plating. The co-culture method with END-2 shows low 
efficiency, but this can be improved with low concentrations of foetal bovine serum (FBS), L-
ascorbic acid and growth factors. The more common technique of EB formation is a more 
reliable method. However, generating cardiomyocytes from iPSCs appears more promising, 
especially as they can be generated from patient specific cells and can be induced to 
differentiate into cardiomyocytes.  
 
The potency of stem cells and progenitor cells to differentiate into diverse cell types has 
been widely documented and reports suggest much promise in regenerative medicine. 
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However, to direct the differentiation of these cells to a particular lineage and to exploit 
these for cell based therapy there is need for clear understanding of the cellular 
mechanisms that mediate their differentiation. Interestingly, the regulatory molecules 
involved in the differentiation of stem cells to cardiomyocytes are identical to those 
expressed/activated during the process of vertebral heart development. Moreover, the 
mechanisms mediating the differentiation of stem cells to cardiomyocytes are comparable to 
those associated with the embryonic development of the heart, the primary organ formed 
during embryonic development. Zygote formed from the fertilized egg, transform into a 
blastocyst comprising the inner cell mass. During the gastrulation, the primitive streak is 
formed and the inner cell mass, forming the epiblastic cells migrate towards the anterio-
posterior direction of the primitive streak to form three distinct germ layers. The mesodermal 
cells further develop into lateral plate mesoderm, intermediate and paraxial. The Lateral 
plate mesoderm further forming the splanchnic mesoderm moves anteriorly and this group 
of mesodermal progenitor cells are called First Heart Field (FHF). These cells differentiate 
and meets at the midline to form the cardiac crescent forming primary heart tube (van den 
Berg et al., 2009). The progenitor cells that are sequentially added to the FHF with 
undifferentiating cells but showing higher rate of proliferation are called Second Heart Field 
(SHF). The heart tubes are further elongated and form chambers, valves, and septa (Evans 
et al., 2010; van den Berg et al., 2009). 
 
The main genes that regulate cardiac development and encode the structural and/or 
regulatory proteins in the heart are Brachyury T, mesoderm posterior 1 (MESP1), GATA 
family, Homeobox Nkx2.5, Myocyte Enhancer Factor 2 (MEF2), Insulin gene enhancer 
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protein1 (Isl1), Heart and neural crest derivatives expressed proteins (HAND1/2) and T-box. 
MESP1 has been recognised as a crucial gene, which acts as a preliminary marker for 
cardiac progenitor cell commitment and fate, and is activated by Brachyury(T) during 
mesoderm formation (Bondue et al., 2008; David et al., 2011; Herrmann, 1992). MESP1 
further up regulate major cardiac progenitor genes like GATA4, Nkx2.5, MEF2C and HAND2 
by downregulating the genes for maintaining pluripotency namely Oct4, Nanog and Sox2. 
 
Cardiac differentiation is initiated by the mesodermal induction of cells with a high level of 
expression of Brachyury T, which causes the induction of specific cardiac progenitor marker, 
mesoderm posterior 1 (MESP1). An increased expression of Brachyury T was used to 
confirm the differentiation of P19CL6 cells into cardiomyocytes by eosinophil cationic protein 
(ECP) (Jin et al., 2012). MESP1, the key regulator further activates cardiac specific genes 
including MEF2C, Isl1, T box transcription factor 5 (Tbx5), HAND1/2, GATA4, and Nkx2.5 
and proteins like Atrial Natriuretic Factor (ANF), MLC-2a, MLC-2v, Myosin heavy chain 
(MHC) and troponin T (Jin et al., 2012). This induction of cardiac lineage commitment 
causes the inhibition or downregulation of pluripotency genes (Bondue et al., 2008; Wu, 
2008). 
 
GATA4 participates in the terminal differentiation of P19 cells into cardiomyocytes (Grepin et 
al., 1997). Studies have shown the direct action of GATA4 is mainly by acting on the 
promoter regions of specific cardiac genes namely -MHC, cardiac troponin I (cTnI), cardiac 
troponin C (cTnC), ANP and MLC (Charron et al., 1999a; Charron et al., 1999b; McGrew et 
al., 1996). In P19 cells and ESCs it was shown that the nuclear factor of activated T-cell 
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(NFAT) regulates the action of Nkx2.5 by the coordinated action with GATA4 during 
cardiogenesis (Chen et al., 2009). Other transcriptional genes required for the normal heart 
development include the MEF2C family, Isl1, and HAND1/2. GATA4 gene is essential in 
heart morphogenesis and myogenesis in mouse and results suggests that a coordinated 
action of Nkx2.5 and MEF2C is necessary for the formation of the ventricle (Lin et al., 1997; 
Vincentz et al., 2008). The overexpression of MESP1 leads to the up regulation of GATA4, 
Nkx2.5 and MEF2C (David et al., 2011). T box transcription factor 5 (Tbx5) is a critical 
transcription factor during cardiac development. Essentially, during morphogenesis, it is 
expressed in the heart tube and its mutation lead to septal defect in heart in the case of 
Holt-Oram Syndrome. Tbx5 is closely associated with Nkx2.5 during cardiac differentiation. 
Previous studies suggest they act cooperatively by being both closely attached to the 
promoter region of cardiac-specific natriuretic peptide precursor type A (Nppa) (Basson et 
al., 1997; Hiroi et al., 2001; Horb et al., 1999). HAND1 and 2, which belong to the Twist 
family of proteins, also play critical roles in early cardiogenesis and within the development 
of the heart, facilitating maturation of ventricular cardiomyocytes and mesothelial cells 
formed in the epicardium. During looping of the heart tube, the expressions of HAND genes 
are elevated and HAND1 specifically on left ventricular outer curvature and HAND2 on 
outflow tract, and right ventricle (Barnes et al., 2010). 
 
The major extracellular signalling molecules involved in regulating differentiation include 
Wnt, FGF, TGF superfamily (Bone morphogenetic proteins, TGF-, Nodal), Notch, and 
Hedgehog signalling proteins (Klaus et al., 2007; Li et al., 2010; Taha et al., 2008; Wang et 
al., 2006; Yu et al., 2011). Studies have indicated that Wnt signalling activates formation of 
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lateral mesoderm, morphogenesis of cardiac cushion and valve formation (Hurlstone et al., 
2003; Ueno et al., 2007). Similarly, in mESCs Wnt signalling decreased contraction in EBs 
and led to a reduction in differentiation (Liu et al., 1999; Naito et al., 2006). There are three 
major pathways for Wnt signalling, a canonical and two non-canonical pathways namely, the 
planar cell polarity pathway (PCP pathway) and the Ca2+/Wnt pathway. Canonical Wnt 
signalling or the Wnt/-catenin pathway is activated when Wnt binds to the Frizzled proteins 
(Fz proteins) and interacts with its co-factor low-density lipoprotein receptor-related protein 
5/6(LRP5/6) to form a complex. The PCP pathway, in contrast, does not involve -catenin 
and co-factors, however the Wnt/Fz proteins activates DSH and stimulate the small G-
protein Rho and Rac subsequently stimulating Rho-associated kinase (ROCK) and c-Jun N-
terminal kinase (JNK), respectively (Endo et al., 2008). Bone morphogenic protein (BMP) 
signalling is also crucial in each of the stages of cardiomyocytes formations, namely 
precardioblast stage, cardioblast stage and cardiomyocytes formation stage. Similar to Wnt 
signalling, BMP signalling has been reported to play a pivotal role in cardiogenesis and stem 
cell differentiation. In addition BMP additionally plays a roles in self-renewal, cell 
proliferation, migration, and apoptosis (Monzen et al., 2002). Studies have also indicated the 
role of BMP signalling in the formation of first heart field and second heart field (Klaus et al., 
2007). There are a multitude of other signalling pathways and molecules implicated for 
cardiac lineage commitment which may be directed by the various extracellular stimuli and 
these are further discussed below (Chapter 4). 
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1.2.5 Clinically relevant inducers of stem cell differentiation 
One of the other challenge facing the field of translational stem cell research is the fact that 
although differentiation has been induced and successfully, this has been achieved using 
agents which may have limited clinical applications. Most of the experimental studies carried 
out to date have used agents such as growth factors including Epidermal growth factor 
(EGF), FGF-4, Hepatocyte growth factor (HGF), (Mummery et al., 1993) organic solvents like 
dimethyl sulphoxide (Skerjanc, 1999) hormones such as Oxytocin (Paquin  et al., 2002) or 
chemicals such as 5-azacytidine (Choi et al., 2004). There is therefore a need to identify 
more suitable and preferably endogenous molecules that may be more clinically relevant in 
regenerative medicine. In this regard, our research has focused on identifying endogenous 
mediators that have a potential to regulate the differentiation of stem cells into 
cardiomyocytes. One such molecule is the lysophosphatidic acid. 
1.3 Lysophosphatidic acid (LPA)  
Lysophosphatidic acid is a derivative of phospholipids with the molecular formula C21H41O7P 
and has a molecular mass of 436.52 kDa. It is considered as an important bioactive 
mediator modulating various biological effects depending on its cellular targets 
(Moolenaar et al., 1997). Lysophosphatidic acid is a simple glycerophospholipid, which is 
exceptionally water soluble and exists in two 1-alkyl- and alkenyl-ether forms (Anliker et al., 
2004).The most commonly used in experiments and commercially available LPA is an 
unsaturated form called oleoyl-LPA or 18:1 LPA (Figure 1). LPA is soluble in water as it has 
a free hydroxyl and phosphate moiety (Jalink et al., 1990; Xie et al., 2002; Xie et al., 2002). 
It was first identified as the Darmstoff’s active ingredient (smooth muscle-stimulating 
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substance) that is present in serum. Biological fluids such as saliva, aqueous humour, 
seminal and follicular fluids and malignant effusions from several cancers, including ovarian 
cancer ascites fluid also contains LPA (Hama et al., 2002; Liliom et al., 1998; Tokumura 
et al., 1999; Xu et al., 1995; Xu et al., 1998). 
 
 
 
 
Figure 1. Lysophosphatidic acid (1-acyl-sn-glycerol-3-phosphate) (LPA),  
M.F-C21H41O7P 
 
41 
 
Lysophosphatidic acid carries a phosphate group, a fatty acid chain and glycerol moiety. 
There is a hydroxyl group at the sn-2 (or sn-1) position, a phosphate group at the sn-3 
position, and a fatty acid chain at the sn-1 (or sn-2) position (Hopper et al., 1999). In body 
fluids, LPA can exist as a long chain of saturated or unsaturated fatty acid linked to glycerol 
moiety with acyl or alkyl groups (Xiao et al., 2000). However, LPA with unsaturated fatty 
acid linkage is more biologically active than the LPA linked to saturated fatty acid (Yoshida 
et al., 2003). The selectivity of the functional relationship with cell receptors depends on 
the information on the structure.  The  fatty acid components in LPA are different from the 
acyl groups of LPA produced from platelets in serum and plasma (Sano et al., 2002). The 
normal concentration of LPA in serum ranges between 1 and 5 M. Interestingly, the LPA 
generated in the circulation by activated platelets ranges between 2 and 20 M (Baker et 
al., 2002; Eichholtz et al., 1993). Production of LPA due to increased cellular activations are 
triggered by several stimuli and agonists during the process of inflammation, blood clotting, 
or wound healing which cause an increase in local LPA production and activity.  
1.3.1 Metabolism and transport of lysophosphatidic acid 
Lysophosphatidic acid synthesis takes place intracellularly and extracellularly by specific 
enzymes. Studies have shown that LPA is the key transitional product in the intracellular 
synthesis of lipids namely triglyceride (TG) and phospholipids (PL) in all cells (Gerrard 
et al., 1989; Mauco et al., 1978; Pages et al., 2001). It exists in a saturated (16:0 and 18:0) 
and as an unsaturated (16:1, 18:1,18:2, and 20:4) form (Eichholtz et al., 1993). In the 
endoplasmic reticulum and in mitochondria, glycerophosphate acyltransferase (GPAT) 
catalyses the synthesis of LPA by means of acylation of glycerol-3-phosphate (G3P). In 
mitochondria, monoacyl glycerol (MAG) through the activities of monoacyl glycerophosphate 
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acyltranferase (MAGT) is converted to phosphatidic acid (Vancura et al., 1992). 
 
Alternatively, in mitochondria and microsomes LPA is also synthesised from MAG by MAG-
kinase, which is involved in the production of phosphatidyl inositol synthesis (Gerrard et al., 
1989; Pages et al., 2001). Di-acyl-glycerol (DAG) processed to LPA via the phosphorylation 
and hydrolysis of the long fatty acid chain. Phosphorylation of DAG is catalysed by DAG-
kinase or an agonist stimulated phospholipase D (PLD) resulting in phosphatic acid (PA). 
 
 
In peroxisomes in pancreatic islets under high glucose concentration, LPA is synthesised 
by the reduction of dihydroxy acetone phosphate (DHAP) which is converted to acyl DHAP 
with the help of an acyltranferase. This, reductase enzyme acts on the latter to produce 
phosphatidic acid. This pathway predominately takes place in the peroxisomes (Dunlop 
et al., 1985). 
 
Other major intracellular enzymes which are involved in the production of LPA include 
phospholipase D (PLD), phospholipase A1 (PLA1) and phospholipase A2 (PLA2) (Mauco 
et al., 1978). Phospholipase A1 and phospholipase A2 produce LPA by acting on 
phosphatidic acid. Another major pathway for LPA synthesis is the plasma enzyme 
LysoPLD, autotaxin (ATX) from lysophosphatidylcholine. Autotaxin is a nucleotide 
pyrophosphatase/phosphodiesterase family m e m b e r  and is present in cerebrospinal 
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and seminal fluids. Reports  suggest  that the level of ATX is noticeably increased in 
patients with B-cell follicular lymphomas, Hodgkin-lymphomas and haematological 
malignancies (Masuda et al., 2008). There are correlations between these conditions with 
elevated LPA concentration in plasma however the cause of this elevation is not yet fully 
understood (Valet et al., 1998). Plasma LPA is mostly found bound to albumin and 
protected from enzymatic digestion by phospholipases (Tigyi et al., 1992). To elicit the 
biological activities in serum and to prolong its physiological half-life in the circulatory 
system it is important that LPA be bound to albumin. Intracellularly, it is transported by 
binding fatty acid binding protein (Thumser et al., 1994). Another mode of transport is 
binding to gelsolin, an actin-binding protein that is a key regulator of actin filament 
assembly and disassembly and by means of lipoproteins (Meerschaertet al., 1998). The 
enzymes lipid phosphate phosphohydrolases (LPPs) which include LPP1/PAP2A, 
LPP3/PAP2B, and LPP2/PAP2C are the main enzymes involved in the maintenance of 
LPA homeostasis. These membrane bound LPPs dephosphorylate LPA to 
monoacylglycerol and PA. The nuclear phosphohydrolase which is yet to be identified also 
contributes to LPA degradation (Baker et al., 2002). Report suggests that an LPA 
specific lysophospholipase ( 80kDa), purified from rat brain, can also catabolise LPA by 
hydrolysing the acyl chain from the glycerol backbone. This group of lysophpospholipases 
has high affinity towards 1-oleoyl and 1-stereoyl rather than 1-palmitoyl and 1-myristyl-
LPA. 
 
The third enzyme known as 1-acylglycerol 3-phosphate acyltransferase (AGPAT)/ 
lysophosphatidic acid acyltransferases (LPAAT) catalyses the esterification of the sn-2 
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position of LPA to form PA. Here, Acyl-COA acts as a substrate for the reaction (Yuki et al., 
2009; Koeberle et al.). So far, five family members of LPAAT have been identified; 
LPAAT/1-AGPAT 1,LPAAT/1-AGPAT 2), LPAAT/1-AGPAT 3, LPAAT/1-AGPAT 4, and 
LPAAT/1-AGPAT 5. Of these, LPAAT shows a higher affinity towards LPA over the other 
members of the family (Aguado et al., 1998). 
1.3.2 Biological effects of LPA 
1.3.2.1 Role of LPA in the vascular system 
Previous studies suggest the influence of LPA in vascular development and formation of the 
vasculature (Smyth et al., 2008; Teo et al., 2009). The main functions regarding the vascular 
system are vasculogenesis, angiogenesis, which also includes proliferation and migration, 
vascular maturation and blood-brain barrier formation (Choi et al., 2010). 
 
The studies conducted in autaxin (ATX) deficient mice showed high vascular defects in yolk 
sac and embryo which were embryonically lethal and were deficient of allantois and neural 
tube formation, suggesting that ATX is the major source for LPA production and shows the 
observed pathological effects in the ATX null mice (Tanaka et al., 2006). LPA may also 
cause activation of platelets during vascular injury and bind to integrins on the vessel walls. 
This subsequently leads to thrombus formation initiated by serotonin and thromboxane A2 
(TXA2), reducing blood flow. LPA also leads to proliferation of vascular smooth muscle cells 
(VSMC) (Gennero et al., 1999). The above mentioned role on cell proliferation along with 
the migratory action of cells stimulated by LPA has beneficial effects in wound healing 
suggesting that LPA has some potential beneficial properties in the body. LPA is also 
reported to be a cardio protective molecule under hypoxia or hypoxia/serum deprived 
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induced apoptosis in mesenchymal stem cells and in cardiomyocytes (Chen et al., 2008; 
Karliner, 2004). 
1.3.2.2 Role of LPA in the Neuronal system 
The neuronal system is the major reservoir for LPA receptors. LPAR1 on the ventricular 
zone (VZ) of cortical neurons has been cloned. Further research has demonstrated the 
effects of LPA on neuroblasts includes cell proliferation (Chun et al., 2002) morphological 
changes such as cellular and nuclear rounding (Fukushima et al., 2002) and alteration in 
the ionic conductance which contributes to cortical neurogenesis (Dubin et al., 2010). Most 
of the LPA receptors are present in astrocytes, neurons, Schwann cells, oligodendrocytes 
and microglia (Noguchi et al., 2009). Other major roles of LPA in neuronal system include 
growth cone collapse, neurite retraction, cerebral cortex growth and folding, cell 
adhesion, anti-apoptotic actions in Schwann cells and migration (Tigyi et al., 1996; Zheng 
et al., 2004). LPAR1 is involved in the proliferation and differentiation of neural progenitor 
cells (NPC) and cultures of neurospheres. However, LPAR4 has also been reported to 
induce differentiation of immortalised hippocampal progenitor cells (Rhee et al., 2006). 
These roles of LPA on the neuronal system show the significant involvement of LPA in 
neuronal disorders like schizophrenia and neurological pain through LPAR1 (Inoue et al., 
2004). 
1.3.2.3 Role of LPA in Cancers 
LPA has been shown to have major roles in pro-tumorigenic activity. Reported studies 
indicated the effects of LPAR1, LPAR2 and LPAR3 receptor mediate proliferation of 
tumours. These are mainly in the ovarian and gynaecological as well as lung cancers and 
little is known about the involvement in prostate cancer, mesothelioma, and glioma. The 
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elevation of LPA concentration in the plasma and ascitic fluid is yet to be explained. In 
ovarian cancer cells, LPA has been reported to induce cell survival, invasion, migration, 
proliferation that involves activation of metalloproteinase and vascular endothelial growth 
factors. These are reported to be mediated through LPAR2 receptor. LPA mediates 
angiogenesis, which further influence the neovascularisation of the tumours. Microvesicles 
released during apoptosis or malignant ascites contributing to high LPA production as in 
case of cancer patients (Mills et al., 2003). 
1.3.2.4 Role of LPA in the Reproductive system 
LPA mediated cellular signalliing plays diverse role in mammalian reproduction and reported 
to regulate spermatogenesis, development/implantation/spacing of embryo, fertilization, 
pregnancy maintenance (Hama et al., 2007; Sordelli et al., 2012; Ye et al., 2010). A 
previous study has also shown that LPA signalling is crucial for blastocyst formation in 
vertebrates (Kobayashi et al., 1994). A role for LPA in the reproductive system is linked to its 
production and release in the endometrium and in addition, LPA receptors are expressed in 
the endometrium. Moreover, LPA modulates prostaglandin (PG) synthesis and maintain 
early pregnancy in bovine species. This is mediated through LPAR3 that is expressed in the 
bovine endometrium. (Woclawek-Potocka et al., 2009). It has also been reported that the 
presence of LPA receptors on the mouse blastocyst during embryogenesis partially helps in 
calcium signalling mediated effects on autocrine and paracrine signals (Liu et al., 2004). 
Similarly, LPA has an important role in the transactivation mechanism through heparin 
binding EGF-like growth factor, triggering the differentiation of mouse blastocyst (Armant, 
2005). 
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1.3.3 LPA receptors 
Previous studies have indicated that LPA- stimulated biological activities are coupled through 
G proteins. The heterotrimeric G protein is composed of a  subunit and a  complex. The 
inactive G protein bound to the receptor on binding of ligand undergoes conformational 
change and becomes active and dissociates from the receptor. Thus the equilibrium changes 
from the inactive G protein to the active state (Rubenstein et al., 2006). They undergo 
activation to actively combine the stimulated receptors to the target (Figure 2). Under basal 
condition the  subunit are in combination with  subunit. On association with the activated 
receptor an exchange of guanosine diphosphate (GDP) with guanosine triphosphate (GTP) 
occurs on the  subunit, and the GTP-bound  subunit detaches from the stimulated 
receptor and the  subunits. These  and  subunits initiate diverse signaling pathway. The 
reassociation of  and  subunits terminates the signaling pathway (Cabrera-Vera et al., 
2003). 
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Figure 2. The process of Intracellular activation of GPCRs and confirmation changes. 
The inactive G protein bound to the receptor on binding of ligand undergoes conformational 
change and becomes active and dissociates from the receptor. Thus the equilibrium changes 
from the inactive G protein to active state and this causes the stimulation of downstream 
signalling events mediated through G protein subunits,  and  
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There are three main G-protein-mediated signaling pathways, mediated by four sub-classes 
of G-proteins distinguished from each other by sequence homology (Gs, Gi/o, Gq/11, and 
G12/13). LPA activated Gq stimulates Protein kinases C (PKC) and increase in Ca
2+ through 
phospho lipase C (PLC). Some of the key effects of Gi/o include inhibition of adenylate 
cyclase (Sunahara et al., 1996); activation of mitogen activated protein kinase signalling; 
stimulation of phosphoinositide 3-kinases (PI3Ks), Ras and then Akt signalling through which 
they show mitogenic and anti-apoptotic effects cells (Hu et al., 2005). Similar effects may be 
mediated through ERKs pathways in fibroblasts (Fang et al., 2000). However, PI3K/Akt and 
ERKs have been reported to be involved in similar effects including cell survival in systems 
such as rat Schwann cells, murine hepato cell line, intestinal epithelial cells (Fang et al., 
2000; Sautin et al., 2001). 
 
Gq is another subunit of heterotrimeric G protein that stimulates PLC. During this process, 
PLC cleaves the phosphatidyl inositol bisphosphate into diacyl glycerol and inositol 
triphosphate (IP3). On dissociation, IP3 remains in the cytosol and bind to the IP3 receptors 
to trigger the release of calcium from endoplasmic reticulum, however DAG stays bound to 
the membrane. The released calcium along with DAG induces PKC triggered signalling 
events. 
 
G12/13 is another subunit of G protein, which, through Guanine Nucleotide Exchange factors, 
regulates various biological activities. G12/13 share 45% amino acid sequence identity with 
the remaining alpha subunits and 67% amino acid sequence identity among each other 
(Harhammer et al., 1996; Strathmann et al., 1991). The major function of Gs is to activate 
50 
 
cAMP dependent pathway by activating adenylate cyclase. Intracellularly, two major 
enzymes; adenylyl cyclase (AC) and cyclic nucleotide phosphodiesterase regulate the level 
of cAMP. The three main targets of cAMPs are protein kinase A (PKA), guanine nucleotide 
exchange factors (GEF), and cyclic nucleotide gated ion channels. PKA plays important roles 
in glycogen metabolism, and inactivates PLC by phosphorylation. PKA also phosphorylates 
tyrosine phosphatase and activates MAPK. In addition, it is also reported to phosphorylate 
Rynodine receptors (Yano et al., 2003) and can modulate ion channel permeability by 
reducing the activity of Raf and Rho (Sassone-Corsi, 2012). 
 
The role of Gi has been examined with a toxin from clostridium botulinum pertussis toxin 
(PTX), which acts as a Gi un-coupler. Pertussis toxin ADP-ribosylates the carboxyl terminal 
sites of most of the Gi/Go family, thereby inhibiting their interaction with the receptor, thus 
uncoupling the receptor from the G-protein. 
 
As previously stated lysophosphatidic acid is a biologically important phospholipid present in 
various tissues and has a wide range of biological activities. Studies revealed that LPA 
binds to specific receptors to mediate its intracellular biological effects (Jalink et al., 1995). 
LPA binding protein was identified with the help of photo affinity study (van der Bend et al., 
1992). LPA was reported as a ligand for ventricularzone-1(VZ-1) receptor first identified and 
isolated from mouse complementary deoxyribonucleic acid (cDNA). This was further 
identified as endothelial differentiation gene, a human homologue of VZ-1 (Hecht et al., 
1996). LPAR1-3 are members of the endothelial differentiation gene (Edg) family (Mutoh 
et al., 2008; Virag et al., 2003). All these LPA receptors belong to the family of seven 
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transmembrane spanning G protein-coupled receptors (GPCRs) and share 45-56% overall 
amino acid identity. Recently used nomenclature for LPA receptors are LPAR1 (Edg-2), 
LPAR2 (Edg-4), and LPAR3 (Edg-7) with the guidelines of the International Union of 
Pharmacology (Contos et al., 2000; Contoset al., 2000; Contos et al., 2000). The newly 
identified receptors includes LPAR4/P2Y9/GPR23, LPAR5/GPR92 (Lee et al., 2007), and 
LPAR6 (GPR87)(Ye, 2008). These receptors are coupled to G-proteins, i.e, G12/13, Gi/o, 
Gq, and probably other G proteins except Gs (Contos  et al., 2000) which have already 
been described above. 
1.3.3.1 LPAR1/ Edg2 
In mouse, LPAR1/ Edg2 gene is localised at centromeric region of chromosome 4 
consisting of multiple exons and introns. It is a 41 kDa protein consisting of 364 amino acids. 
In the central nervous system, it is highly localised in the neo-ventricular zone (VZ) and 
meninges during embryogenesis and expression of LPAR1 continues through the VZ 
disappears during cortical neurogenesis. In-situ hybridisation studies have reported the 
expression of LPAR1 in oligodendrocytes and Schwann Cells (Weiner et al., 1998). In 
addition, LPAR1 mediates its biological effects through the interaction with Gi/o, G12/13 and 
G11/q followed by signalling mechanisms which include inhibition of adenylyl cyclase 
(Hecht et al., 1996), Ca2+ signalling, phospholipase C activation (Hofer et al., 1998) 
activation of the serum response element (Contos et al., 1998) and stimulation of Rho 
signalling (Arimura et al., 1998). 
1.3.3.2 LPAR2/ Edg4 
LPAR2/ Edg4 gene is located at chromosome 8 in mouse, in humans (chromosomal locus 
19p12) and shares 60% homology towards LPAR1. It has a molecular mass of 39kDa with 
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348 amino acid residues (Contos et al., et al., 2000). Similar to LPAR1, its biological 
activities are mediated through Gi/o, G11/q, and Gα12/13 and have multifunctional 
activities. Unlike LPAR1, LPAR2 is present in the brain during embryogenesis but 
disappears within 2 weeks after birth. In mouse, LPAR2 is highly expressed in uterus, 
kidney, and testis but expression of LPAR2 receptors is moderately present in lung and 
much lower in heart, stomach, spleen and thymus. In human tissues, high expression of 
LPAR2 is detected in testis and leukocytes, with moderate expression found in prostate, 
spleen, thymus, and pancreas. This highlights the targets and the potential of LPAR2 gene 
and its oncogenic role in addition to its role in cell migration and survival ( G o e t z l  e t  
a l . ,  1 9 9 9 ;  Z h e n g  et al., 2 0 0 1 ) .  
1.3.3.3 LPAR3/ Edg-7 
Another edg family member of the LPA receptors is the LPAR3/ Edg-7. Human forms of 
LPAR3 consist of 353 amino acid residues and 40.1 kDa of estimated molecular weight 
(Bandoh et al., 1999). It is predominantly present in prostate, heart, testis, pancreas, lung, 
ovary and brain in human. In mouse it is mostly present in kidney, small intestine, 
heart, stomach, thymus, brain, lung, spleen, testis (Contos et al., 2002; Kingsbury et al., 
2003; Sardar et al., 2002). Reports suggest that the major actions of LPAR3 are 
mediated through Gαi/o, Gα11/q and shows lower response towards saturated LPA than LPA 
bound to unsaturated fatty acids (Bandoh et al., 1999). 
1.3.3.4 LPAR4/P2y9 
LPAR4/P2y9 is an integral G-protein-coupled receptor which has high affinity towards 1-
oleoyl LPA with a Kd value of 45 nM and sharing 20-24% amino acid sequence identity 
towards Edg receptor family (Noguchi et al., 2003). LPAR4 shows a closer identity towards 
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the P2Y receptor than Edg family (20-24 %) (Yanagida et al.,2007). Its affinity towards 
the LPA analogues is shown in the order of 18:1- > 18:0- >16:0- > 14:0- > 1-alkyl- > 1-
alkenyl-LPA (Noguchi et al., 2003). In humans, LPAR4 is ubiquitously present with the 
highest expression in the ovary. The main reported effects are induction of Ca2+ 
mobilisation, cAMP accumulation, cell rounding, and stress fibre formation. These 
reported effects are mediated through G-proteins mainly Gs, Gq11 and G12/13. However, 
LPAR4 shows suppressive effect on cell motility, cell migration in B103 cells and invasion of 
colon cancers (Lee et al., 2008). 
1.3.3.5 LPAR5/GPR92 
In human, the LPAR5 gene is located on chromosome 12p13.31 and encodes a 41-kDa 
protein consisting of 372 amino acids, sharing 35% homology with LPAR4. It has been 
reported to be well expressed in tissues like the heart, skin, spleen, small intestine, 
stomach, thymus, liver, embryonic brain and embryonic stem cells, B cells, intestinal CD8+ 
lymphocytes, and platelets (Kotarsky et al., 2006). The major biological activities mediated 
through LPAR5 include LPA-induced neurite retraction, stress fibre formation mediated 
through G12/13, increasing intracellular calcium through Gq and increasing cAMP levels. 
Recently identified lipid-derived molecules (farnesyl pyrophosphate and Narachidonylglycin) 
were characterised as LPAR5 ligands (Yoon et al., 2008). 
 
Other recently identified receptors which can mediate the biological effects of LPA are 
LPAR6/GPR87, LPAR7/p2Y5, and LPAR8/p2Y10 (Murakami et al., 2008; Pasternack et 
al., 2008). LPAR6/GPR87 is mainly expressed in brain, skeletal muscle, and the 
reproductive organs. LPAR7/p2y5 is found in the skin and hair. P2Y5 was identified as 
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a critical mediator for human hair growth and is a causal gene of a rare familial form of 
human hair loss (Pasternack et al., 2008). LPAR8/p2y10 has been found in the uterus, 
prostate, brain, lung, placenta, and skeletal muscle (Murakami et al., 2008). 
 
Non-GPCR includes intracellular receptor, peroxisome proliferator-activated receptor 
gamma (PPAR) which is a potent ligand for serum lipids like LPA. It shows highest 
response towards the unsaturated LPA species and plays an important role in cell 
proliferation (Hurst-Kennedy et al., 2009) apoptosis (McIntyre et al., 2003). These properties 
explain the role of this receptor in diseases like atherosclerosis, diabetes and cancer. 
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Figure 3. Lysophosphatidic acid (LPA) receptors induced signalling mechanisms 
The figure elucidates the main signalling events mediated by LPA1-5 receptors, coupled 
through G-proteins. The major downstream signalling molecules involved are MAPKs, PI3K, 
PKC and ROCK pathways. 
G12/13 Gq/11 Gi Gs 
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1.4 G Protein Coupled Receptors (GPCRs) and the downstream 
signalling mediated by Lysophosphatidic Acid 
As already indicated above, GPCRs trigger various biological activities in cellular systems 
and these are mainly by the involvement of major signalling molecules such as PI3K, PKC, 
ROCK, and through small GTPase activating the downstream of Akt or MEK pathways. The 
detailed overview of signalling events briefed below. 
Phosphoinositide 3-kinases are mostly present in all cells and regulate cellular responses 
like proliferation, growth, migration, differentiation, survival, apoptosis and even cell cycle. 
These are mainly activated via heterotrimeric G Protein subunits Gi, Gq and G PI3Ks are 
subdivided into 3 subclasses. Class I is a heterodimeric protein having a catalytic and 
regulatory subunit. It is also further divided into IA and IB subtypes. Class IA PI3Ks have a 
p85 regulatory and p110 catalytic subunits. Class III are heterodimeric enzymes with a 
catalytic and regulatory site but class II PI3Ks are monomeric proteins with very little known 
about these enzymes (Elis et al., 2008). Receptor tyrosine kinases (RTKs) (Class I PI3K) and 
GPCRs activates their downstream target, class IB PI3Ks. PI3K catalyses the formation of 
phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) by transfer of a gamma phosphate of ATP 
to the 3’-OH position of the inositol ring of membrane bound phosphatidylinositol (4, 5)-
bisphosphate (PIP2). Further, this activates a downstream enzyme, Akt or protein kinase B 
(PKB) that is a serine/threonine protein kinase. This is mediated by phosphatidylinositol 
dependent protein kinases PDK-1 and PDK-2 on the plasma membrane by which the Akt 
enzyme becomes completely active. PDK1 catalyses the phosphorylation of Akt in the 
domain active loop at threonine 308 and PDK2 phosphorylates at serine 473. PI3K/Akt plays 
a vital role in activating crucial effector molecules including the induction of c-myc and Bcl-2, 
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phosphorylation of 4E-BP1 and activation of translation initiation factor and regulation of anti-
apoptosis. PDK1 has been reported to phosphorylates Protein Kinase C (novel, atypical), 
p70 s6 kinase. The de-phosphorylation and degradation of PIP3 are mediated by tensin 
homolog deleted on phosphatase and tensin homologue (PTEN) and Src homology 2-
containing inositol 5-phosphatase (SHIP) removing 3-phosphate from PIP3 to generate PI (4, 
5) P2 and PI (3, 4) P2 respectively. PI3K has been reported to be involved in differentiation 
of various cells such as trophoblastic cells, osteoblasts, chondrocytes, embryonic stem cells 
(Kentet al., 2010). In addition, PI3K plays a crucial role in differentiation of stem cells into 
cardiomyocytes (Fujita et al., 2004; Kent et al., 2010; Naito et al., 2003; Sauer et al., 1999).  
 
Protein kinase C belongs to a family of protein kinase enzymes that acts by phosphorylation 
of hydroxyl groups on serine and threonine residues in the proteins. They play significant 
roles in cellular mechanisms like proliferation, differentiation, and apoptosis. These are 
mainly activated by high concentrations of diacyl glycerol, which is produced by the action of 
PLC and Ca2+. PKC activation through heterotrimeric G Protein is mainly through Gi/ Gq. 
The PKC family is sub-divided into conventional (c)PKC, novel (n)PKC and atypical (s)PKC 
depending on their requirement of second messengers. Conventional PKCs are , 1, 2 and 
 isoforms, which require Ca2+, DAG and a phospholipid (phosphatidyl serine) for their 
activation. Novel PKCs contain , ,  and theta isoforms and require only DAG for its 
activation and atypical PKC do not respond to either DAG or Ca2+. Structures of PKCs 
consist of a regulatory site and a catalytic site. The regulatory site carries a C1, C2, C3 and 
C4 domains. The C1 domain has high affinity to bind to DAG and phorbol esters. This is 
functional in conventional and novel isoforms of PKCs, but not in the atypical isoforms. The 
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C2 domains acts as a Ca2+ sensor which is present in both (c)PKC and (n)PKC but it is 
functional only in (c)PKC. The catalytic site of PKC consists of the N terminal at the  sheet 
and c terminal at the -helix. The enzyme with two lobes forms a cleft that is also the site for 
ATP, substrate and pseudo-substrate. The activation of PKC is regulated by phosphorylation 
at specific sites. (c)PKC and (n)PKC have three phosphorylation sites called activation loop, 
the turn motif and the hydrophobic motif but the atypical PKC has only activation loop and 
turn motif phosphorylation sites. First, PDK-1 mediated phosphorylation occurs at the 
activation loop of conventional, novel and atypical PKC, which is followed by the auto 
phosphorylation at threonine 450 in the turn motif and serine 660 in the hydrophobic motif 
(Newton, 2003). This event is PIP3 independent; however the PDK-1 driven Akt activation is 
PIP3 dependent (Sonnenburg et al., 2001). Previous reports suggest the importance of PKC 
in the differentiation of various cell types including mESCs, human dental pulp stem cells, 
bone marrow cells (Kiraly et al., 2009; Li et al., 2009).  
 
Other importantly, signalling actions are channelled through multiple signalling pathways 
including the mitogen activated protein kinases (MAPKs). MAPKs are activated by sequential 
phosphorylation of MAP Kinase Kinase Kinase, MAP Kinase Kinase.  However, previous 
reports have indicated that this could be accelerated either by activation or inhibition of these 
MAPK families (Gaur et al. 2010; Li et al., 2002). The MAPKs family include extracellular 
signal regulated kinases (ERK), p38 MAPK, and c-Jun N-terminal kinase (JNK).c-Jun N-
terminal kinase (JNK), these are further discussed in detail (Chapter 4). 
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Aim of the project 
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Evidence over the past decade does suggest that LPA does induce differentiation of 
neuronal and mesenchymal stem cells (Wang et al., 2006; Cui et al., 2007). Interestingly, 
reports have also suggested the importance of LPA during the development of embryo to 
blastocysts/gastrula and it has been reported to act as a cardio protective molecule under 
hypoxic condition and protects MSC against hypoxia/ serum deprived (SD)-induces 
apoptosis, (Chen et al., 2008; Karliner 2004). LPA also plays diverse physiological roles in 
cellular system a s  d i s c u s s e d  a b o v e  a n d  include regulation of cell proliferation, 
differentiation, chemotaxis as well as acting as an anti-apoptotic agent and accumulates in 
the myocardium after an acute infarction. Most of its effects are mediated via signalling 
molecules (discussed above) which also play a critical role in the lineage commitment of 
stem cells. Hence we hypothesise that LPA could be a potential endogenous molecule that 
regulates stem cell differentiation into cardiomyocytes, exerting its effects through distinct 
LPA receptors linked to specific downstream signalling pathways. This study has therefore 
investigated the effect of LPA on the ability of the murine P19 stem cells to differentiate into 
cardiomyocytes and further examined the role of the different LPA receptors and the 
downstream signalling mechanisms associated with the commitment of the P19 cells into a 
cardiac lineage. 
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Chapter 2 
Materials and methods 
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2.1 Resuscitation and culture of P19 stem cell from frozen stock 
P19 mouse embryonal carcinoma stem cells (P19 stem cells) (passage 7) were purchased 
from the European Collection of Cell Cultures (ECACC; Salisbury, UK). One ml of frozen 
P19 stem cells was quickly thawed in 15 ml falcon tube, resuspended in 9ml of fresh 
complete culture medium containing alpha Minimum Essential Medium (-MEM) 
supplemented  with  10% foetal  bovine  serum  (FBS),  100units/ml  penicillin/100g/ml 
streptomycin (all from Invitrogen, UK).  The tubes, containing the cells, were centrifuged at 
1000 RPM at 4oC for 5 minutes. The medium was then aspirated and the pellet was 
separated. The cells were then resuspended in 7 ml of medium and dissociated into single 
cells by repeated pipetting in a T25 flask. Further, the cells were cultured in a cell culture 
incubator at 37oC, 95% air and 5% CO2. 
 
On day 2, cells in the T25 flask were observed under a microscope for normal growth. On 
day 3, the spent media was replaced with fresh medium. The cells were subsequently 
trypsinised and sub-cultured when they were approximately 60-70 % confluent. Following 
growth, cells were harvested and the resulting cell suspension approximately divided into 
five parts (1:5 splitting) and further sub-cultured for future investigations in this thesis. 
 
2.1.1 Routine cell culture 
All P19 cells were routinely cultured in falcon flasks with complete medium maintained at 
37oC, 95% air and 5% CO2. Cells at 60-70% confluence were sub-cultured by removing 
the spent media from the flask and were washed 3 times with warm (37oC) 1X phosphate 
buffer saline (PBS). 1.5 ml of warm 1% of trypsin solution (Invitrogen-UK) was added into 
each flask and vigorously tapped. 8.5 ml of fresh complete medium was added to inactivate 
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the trypsin in the flask and 1 ml of the re-suspended cells was then added to a new T-75 
flask with 14 ml of fresh medium and cultured in an incubator. 
2.1.2 Cryopreservation of cells 
When necessary, cells were stored for future use by trypsinizng cells as above and spun at 
1000 RPM for 5 minutes at 4oC. The supernatant was aspirated and the pellet re-suspended 
in 1 ml of freezing medium containing 90% FBS and 10% glycerol (Invitrogen, UK). The cell 
suspension was aliquoted in cryovials (cells from one T-75 flask were frozen in 2 cryovials 
i.e. splitting ratio of 1:2) and placed in a Thermo Scientific NALGENE® Mr. Frosty (i.e. a 
controlled  rate freezing  container) (Fisher  Scientific, UK) for freezing overnight at -
80oC. The next day, the vials were transferred into liquid nitrogen for long-term storage. 
 
2.2 Embryoid body (EB) formation and differentiation into 
cardiomyocytes 
2.2.1 Cell counting and plating for EB formation 
To initiate differentiation, cells have to form 3 dimensional structures called embryoid body 
(EBs). For this, cell monolayers were treated with 1% trypsin to form a single-cell 
suspension. The pellet was resuspended in full medium. 20l of the cell suspension was 
mixed with equal volume of trypan blue and placed in the Countess electronic cell counter 
chamber. The concentration of viable cells (cells/ml) to be plated from the cell suspension 
was determined in the following example: 
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Viable cells in the cell suspension (1 ml) = 3.1X 106 
 
 
 
Desired concentration of cells/ Petri dish = 3.7X105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence, the volume of cell suspension (x) containing 3.7X 105 cells was calculated. 
 
119.4l of cell suspension was plated into non-tissue culture grade microbiological Petri 
dishes with 4880.6 l of full medium. 
2.3 Initiation of P19 cell differentiation with 1% DMSO 
Semi confluent P19 cells (3.7x105) were seeded into ultra-low attachment petri dishes 
containing full medium and left to form EBs over 4 days (Figure 4) before plating into normal 
6-well cell culture dishes for differentiation on the fifth day. Initially, to establish a 
differentiation model, confluent monolayer were trypsinised and treated with 1% DMSO 
during the EB formation phase. Embryoid bodies plated into normal cell culture dishes 
were allowed to attach and grow into monolayers, changing the medium every 2 days. 
The day of plating the EBs into cell culture dishes was designated as day 0. Whole cell 
lysates were generated at days 2, 4, 6, 8, 10 and 12.  In parallel, studies were also 
conducted to look at the effects of seeding density of EBs on efficiency of differentiation. 
Embryoid bodies were formed from a predetermined number of P19 cells (3.7 X 105 
 
Desired concentration of cells (i.e. 3.7 X10
5
cells)  
Viable cells in the cell suspension (1 ml) (3.1X 10
6
)  
Volume of cell suspension (x) plated =  
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cells/petri dish) in the presence of 1% DMSO. The EBs were then resuspended in 12 ml 
fresh complete culture medium. Various volumes from 0.5, 0.75, 1.0, 1.5, 2.0, 2.5 ml of 
the resuspended EBs were plated into 6 well tissue culture plates. Whole cell lysates 
were generated at day 6 after plating into cell culture dish. Lysates were analysed for their 
total protein content (Section 2.7) and subsequently subjected to western blot analysis 
(section 2.8).   
2.4 Initiation of P19 cell differentiation with LPA 
To induce differentiation with LPA, the culture medium was supplemented with 18:1 LPA 
purchased from Sigma Aldrich and dissolved in 1X PBS containing 0.1% fatty acid free 
bovine serum albumin. LPA solutions was added at concentrations of 1M, 5M, 10M 
o r  25M immediately before the cells were seeded into the non-tissue culture grade 
microbiological Petri dishes and prior to EB formation. In parallel studies 1% DMSO was 
used in place of LPA as a positive control for the induction of P19 cells into 
cardiomyocytes.  
 
Cell lysates were generated at different time points at days 6 and 12 after plating into cell 
culture dish. Whole cell lysates were also generated for time course studies at days, 2, 6, 10 
and 14 days after plating into cell culture dish. Lysates were analysed for their total protein 
content (Section 2.7) and subsequently subjected to western blot analysis (Section 2.8) for 
the cardiac-specific MLC-1v. 
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Figure 4. Induction of differentiation of P19 stem cells into cardiomyocytes. 
Embryoid bodies were formed from P19 stem cell in differentiation medium consisting of α-
MEM supplemented with 10% FBS, 100 units/ml penicillin, 100 g/ml streptomycin and LPA 
or 1% DMSO for four days. The EBs were transferred into standard cell culture dishes and 
cultured over a period of up to 12 or 14 days. For the study carried out for the time course on 
the induction of differentiation, Lysates were generated at different time points (days- 2, 6, 10 
and 14) and for the concentration dependent studies lysates were generated on day 6 and 
12 as required.  
(DAYS) 
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2.5 Effects of receptor/signalling inhibitors on P19 stem cell 
differentiation into cardiomyocytes induced by LPA  
Cells (3.7x105) were seeded into ultra-low attachment petri dishes containing complete 
medium and allowed to form EBs over 4 days as described above. Where an inhibitor for a 
receptor or signalling was used, cells were treated with the inhibitor for 60 min before 
the addition of 5M LPA. When used, pertussis toxin (PTX; 100 and 200 ng/ml) cells were 
incubated for 24 hours before the addition of LPA. Inhibitors were kept in the medium 
throughout the EBs formation stage. On day 5, EBs were transferred into 6 well cell culture 
dishes containing full medium which was changed every 2 days. Monolayers of cells were 
lysed on day 6 after plating in the 6 well plates for the detection of MLC-1v by western blot 
analysis. 
 
The inhibitors used were Ki16425 (1, 10 and 50 M) purchased from Cambridge 
Biosciences (Cambridge, UK), suramin (Sigma Aldrich, UK), Y-27632 (1, 5 and 10 M; 
Calbiochem, UK), SB203580 (1 and 10 M), LY294002 (1, 2, 5, 10 and 20M), Akt inhibitor 
XIII (0.1, 0.5 and 1.0 M)  and  bisindolylmaleimide I (0.1, 0.5, 1.0, 5.0 and 10M) from 
Merck Chemicals Ltd, UK. 
2.6 Time course of phosphorylation of Akt, p38 MAPK and ERK1/2 and 
effects of inhibitors on phosphorylation induced by 5M LPA  
For time course study, P19 cells were seeded into petri dishes at a density of 2X104 cells/ml 
in complete growth medium and placed in the incubator for normal growth. When cells were 
70% confluent, the culture medium was removed. The cells were then supplemented with 
low serum containing growth medium (1% FBS) and serum starved for a period of 24 hours. 
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Cells were eventually either incubated in fresh medium alone or in medium containing 5M 
LPA for a time point of 0, 1, 3, 5, 10, 15, 30 or 60 minutes. In parallel dishes, cells were pre-
treated with either receptor or specific signalling inhibitors for 60 minutes before LPA 
treatment for selected time points. Each P35mm petri dish was lysed on ice with the (1X) 
lysis buffer (Section 2.7) containing 1:100 dilution of a phosphatase inhibitor cocktail (Sigma 
Aldrich, UK). The lysates were then stored at -20oC until analysed by western blotting using 
kinase-specific primary monoclonal antibodies. Antibodies for phospho-Akt (Ser473), 
phospho-p38 MAPK and phospho-ERK1/2 were purchased from Cell Signaling Technology, 
(UK).  
2.7 Cell lysis and quantification of proteins 
Cell monolayers were washed 3 times with 1X ice-cold PBS and lysed by adding 350l of 
ice-cold lysis buffer (2 mM Tris-HCl, pH 7.4, 1% SDS). Lysates were transferred i n to 1.5 
ml micro-centrifuge t u b e s  and heated at 95oC for 5 minutes followed by sonication 3 
times, 30s each cycle. Cell lyses for phospho-proteins were generated using 1X lysis buffer 
containing phosphatase inhibitor (1:100). Lysates were then centrifuged and the 
supernatant was used for analysis. Total cell protein was colorimetrically quantified using 
the bicinchoninic acid (BCA) assay reagent (Smith et al., 1985). The peptide bonds of 
proteins reduces cupric (Cu2+) ions to cuprous (Cu+) ions, which further chelates with two 
molecules of bicinchoninic acid forming a purple colour complex measured at 620 nm. A 
protein standard was prepared with bovine serum albumin (BSA) by dissolving 10mg/ml of 
BSA in double distilled water. This was then diluted as shown in Table 1 below to give the 
required concentration range of standard proteins. 
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Table 1. Preparation of working BSA standards 
 
 
The volumes of 10 mg/ml BSA as indicated in Table.1 were diluted with the appropriate 
volumes of double distilled water to give the final concentrations indicated. 5l of each 
concentration was used to set up the standard curve as described below.  
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A 96 well plate was set up as follows: 
 
a. Control wells: 5l double distilled water (DDW) + 5l lysis buffer + 100l BCA. 
b. Standards: 5l standards + 5l lysis buffer + 100l BCA.  
c. Sample wells: 5l DDW + 5l lysate + 100l BCA. 
 
 
The plates were incubated at room temperature for 45 minutes on a shaker and the 
absorbance determined by using a Multiskan II plate reader (Ascent, BCA protocol) set at a 
wavelength of 620 nm. Protein concentration for each sample was determined from the BSA 
standard curve. A sample standard curve is shown in Figure 5 below. A standard curve is 
constructed using the absorbance reading of the series of standards against the known 
concentration of the standards. The concentration of protein in samples was determined 
using the formula y= mx+c.   
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Figure 5. BCA Protein standard curve 
The quantification of protein for western blot analysis was determined using the BCA assay. 
The standard curve was constructed by plotting known concentrations (ranging from 0-5 g/l) 
on x- axis against the absorbance of the standards on y-axis. Concentration of protein in the 
sample was then calculated using this standard curve with the slope and the formula y=mx+c. 
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2.8 Western Blotting 
Protein lysates were separated and resolved using sodium dodecyl sulfate- polyacrylamide 
gel electrophoresis (SDS-PAGE). This comprised of cell lysates preparations, separation of 
lysates proteins by gel electrophoresis, transfer of proteins from gel to a membrane, 
immunoblotting and detection of protein band using enhanced chemiluminescence. 
2.8.1 Sample preparation and gel preparation 
A known volume of cell lysates for loading 25 g of protein was mixed with equal volume of 
2X sample buffer containing SDS (4%), glycerol (10%), -mercaptoethanol (2%) and 
bromophenol blue 0.006%), Tris-HCl, pH6.8 (250 mM). The gel electrophoresis was carried 
out on a Bio-Rad Mini-PROTEAN II casting stand (Bio-Rad, UK). The resolving gel (12 %) 
was prepared for two gels as follows: double distilled water (3.31 ml), 30% 
acrylamide/bisacrylamide (3.99 ml), 1.5M Tris-HCl, pH8.8 (2.5 ml), 10% sodium dodecyl 
sulphate (SDS) (0.1 ml), 10% ammonium persulfate (APS) (0.1 ml) and N, N, N′, N′- 
tetramethylethylenediamine (TEMED) (6l). The solution was mixed well and 4 ml was added 
between the glass plates for polymerisation. A thin layer of iso-butanol was layered on top to 
prevent air contact and to allow the formation of a uniform layer. After polymerisation of the 
resolving gel the layer of iso-butanol was removed, rinsed with distilled water and dried well. 
The 8% stacking gel was prepared as follows: ultra-pure water (5 ml), 30% acrylamide/0.8% 
bisacrylamide solution (1.3ml), Tris-HCl (0.5M; pH 6.8) (2.5 ml), 10% SDS (0.1ml), of 10% 
ammonium persulfate (0.05ml) and TEMED (0.01ml). The stacking solution was mixed well 
and added on top of the resolving buffer .  1 mm Teflon comb was placed in the gel to 
form loading wells for the samples. This was kept for polymerisation for 30 minutes. The 
comb was removed after the polymerisation and the gel was placed in the electrophoresis 
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tank with 1% tank buffer (0.025M Tris, 0.192M glycine and 0.1% SDS). The samples 
mixed with 2X sample buffer were boiled at 95oC for 3-5 minutes and 25g of protein was 
loaded into each well along with 5l of molecular weight ladder in the last well. The 
electrophoresis was run at 20mA/gel for stacking the samples and changed to 25mA/gel for 
resolving. The electrophoresis was performed at a voltage of 220 V until the tracking dye 
reached the bottom of the resolving gel. 
2.8.2 Transfer of proteins from gel to polyvinylidene difluoride PVDF membrane 
The proteins were transferred from the gel to the polyvinylidene difluoride (PVDF) membrane 
in a semi-dry transfer cell (Trans-Blot SD, Bio-Rad) using 1X transfer buffer consisting of 
48mM Tris base (pH 7.5), 39mM glycine, 0.0375% SDS and 20% methanol. The PVDF 
membrane was treated with methanol for 30 seconds followed by washing with distilled 
water. This removes the hydrophobicity of the membrane. The gels were then removed 
from the electrophoresis tank and placed on top of the PVDF membrane. These were 
sandwiched between two filter papers soaked in transfer buffer. The transfer of proteins was 
carried out for 20 min at 25 volts. 
2.8.3 Blocking of membrane and detection of protein bands by enhanced 
chemiluminescence (ECL) 
Membranes were blocked for one hour at room temperature or overnight at 4oC in blocking 
buffer to prevent non-specific binding of the antibody. For this, 100ml of blocking buffer was 
prepared with 10ml of 10X Tris Buffer Saline-Tween (TBS-T) washing buffer (100 mM NaCl, 
10 mM Tris (pH 7.4)), 0.1% (v/v) of Tween-20 was added on the day to the 1X diluted 
buffer, 5% (w/v) of non-fat skimmed milk was also added to the blocking buffer just prior 
to use. Membranes were then probed with the primary antibody which was a mouse 
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primary monoclonal antibody against MLC-1v (1:500; ab680, Abcam, Cambridge, UK). The 
secondary antibody used was a horseradish peroxidase conjugated mouse mAb against -
actin (1:5000; Sigma Aldrich, Dorset, UK). At the end of the incubation period with primary 
antibody, the membrane was washed at least 3 times with Tris buffer saline-tween 20 (TBS-
T) before being incubated with the goat-anti mouse horseradish peroxidase conjugated 
secondary antibody (1:5000; Cell Signalling Technology, UK) for 1 h followed by 3x washes 
with TBS-T. All antibody dilutions were in blocking buffer. The bands were visualised using 
the ECL reagent. For this, equal volumes of ECL reagent 1 (5ml of 100 mM Tris pH8.5 + 25l 
of 90 mM p-coumaric acids + 50 l of 250 mM luminol) and reagent 2 (5ml of 100 mM Tris 
pH8.5 + 3l of 30 % H2O2) were mixed, and applied over the membrane for 1 minute. Excess 
ECL solution was drained off and the membrane covered with cling film avoiding trapping air 
bubbles. An autoradiography hyperfilm (Amersham, UK) was then placed over the 
membrane and left in the cassette for the desired time. The film was immediately developed 
using Kodak DEKTOLTM developer  and  fixed  with  Kodak  UNIDIXTM  fixer. The protein 
bands were then quantified using image-j densitometry. 
2.9 Cell viability assay 
The cell viability assay also called the3-[4, 5-Dimethylthiazol-2yl]-2, 5-diphenyl tetrazolium 
bromide (MTT) assay was performed to establish the cytotoxicity of any drug used in the 
study. Metabolically active cells reduce MTT to insoluble formazan crystal that was 
measured colorimetrically at 540 nm. This enzymatic conversion of MTT was used as an 
index of cell viability (Slater et al., 1963). Cells were seeded in 96-well plates and treated 
with a range of concentrations of the different drugs in full medium for 24 hours. 20L of 
MTT solution (5mg/mL) was added to each well and incubated for 4 hours. The medium 
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was removed and formazane crystals were dissolved in 100l iso- propanol and absorbance 
was read at 540nm on a Multiskan II plate reader (Ascent, MTT protocol). Viability was 
expressed as a percentage of control untreated cells. 
 
2.10 Extraction of RNA and RT-PCR study 
To establish the expression profile of LPA receptors in P19 cells, transcripts of the receptors 
were analysed using quantitative PCR (qPCR). In these studies, controls and LPA (5M) 
treated cells in T75 flasks were incubated with 2 ml of the RNA STAT60 reagent and the 
cells lysed by repetitive pipetting. Further extraction of RNA, removal of genomic DNA 
contamination and the reverse transcription of the RNA to cDNA were carried out as 
described below. Changes in mRNA levels for each receptor was normalised by 
amplification of a reference housekeeping gene (HKG), which is essential for the relative 
quantification of cDNA in each target genes in individual reactions. 
 
 
Total RNA was extracted from a confluent layer of cells in a T-25 flask using the RNA 
STAT60 reagent (Amsbio, UK) as per manufacturer’s instructions. The protocol was as 
follows: 2 ml of the RNA STAT60 reagent was added to a monolayer of P19 cells and 
homogenised by repetitive pipetting. The lysates were further incubated for 5 min for 
complete dissociation of nucleoprotein. Following the addition of 0.4 ml of chloroform 
(equivalent to 0.2:1.0 ml, chloroform/lysates) lysates and the contents were vigorously 
mixed, allowed to stand for an additional 5 minutes and then centrifuged at 12,000 RPM 
for 15 minutes at 4oC. Total RNA was precipitated from the top aqueous layer b y  t h e  
a d d i t i o n  o f  0.5 ml of isopropanol followed by incubation at room temperature for 5 min 
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before a final centrifugation step at 12,000 rpm for 15minutes at 4oC. The resulting white 
pellet of RNA was washed 3 times with 1 ml of 75% ethanol with vortexing and centrifuging 
each time before air- d r y i n g  the pellet in a fume cupboard. The pellet was then dissolved 
in 50l of DNAse free water. The RNA was quantified spectrophotometrically at 260nm. The 
purity of the RNA was determined from the 260/280 ratio which was expected to be >1.8 for 
the samples to be considered suitable for analysis. The quality of the RNA was further 
evaluated with RNA electrophoresis visualizing sharp and non-smearing bands for the two 
intact ribosomal bands of 28s and 18s with the intensity ratio of 2:1 respectively. 
 
 
To remove genomic DNA contamination, RNA was next subjected to RNase-free DNase 1 
treatment using Ambion Turbo DNA-free kit. Next, 1g of total RNA was reverse transcribed 
into cDNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Qualitative 
detection of LPA receptor expression was carried out by standard PCR. The 
amplification conditions were as follow: 10 min at 95oC; then 35 cycles of 15 s at 95oC; 1 
min at 60o C; and 10 sec at 72oC followed by dissociation at 58oC to 95oC. Primers for LPA 
receptors1 to 5 were designed using fast PCR, purchased from Primerdesign Ltd, (UK). 
 
The expression of the LPA receptors was then confirmed by running 2% agarose gel 
electrophoresis in 1X TBE buffer (10X Tris borate EDTA (TBE) buffer- 89mM Tris-HCL pH 
7.8, 89 mM borate, 2mM EDTA). The weighed agarose was dissolved in 100ml of 1X TBE 
buffer by heating in a microwave for 2-3 minutes. The content was allowed to cool and added 
0.50 l of Ethidium Bromide and mixed it by swirling. This is them poured into the two sides 
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tapped electrophoresis tray, then placed the comb and the gel was left to set for 30 minutes. 
The gel was then placed in an electrophoresis tank with sufficient volume of 1X TBE buffer to 
cover the top layer of the gel and removed the comb. Each sample 10 l each were then 
loaded into the well along with respective negative controls (nuclease free water) and added 
2 l of the DNA ladder (50bp) (Life Technology, UK). The Electrophoresis was carried out for 
around 60-90 minutes at 100 V until it reaches towards the end of the gel making sure not to 
run off the gel. 
78 
 
Table 2. LPA Receptor Primers 
 
 
 
The PCR amplicon were run on a 2% agarose gel and visualised with ethidium bromide for 
30 minutes. To determine which housekeeping gene would be used, experiments were 
initially conducted to establish the stability of eight potential candidates: ribosomal protein 
L13a (RPL13A), ubiquitin C (UBC), beta 2 microglobulin (B2M), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), beta actin (ACTB), cyclophilin (CYC), tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAZ) and Calnexin 
(CANX). Total RNA was isolated from cultured P19 cells at day 0 and day 6 from untreated 
and 5M LPA treated samples. The RNA was subjected to quantitative RT- PCR as 
described above and the threshold cycle number (Ct) values used in the Genorm software to 
identify the most stable gene. Further, the changes in the expression of LPA receptors were 
quantified using the selected housekeeping gene. 
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Calculation of relative gene expression levels. 
The Ct was noted for both target gene and housekeeping gene in each reaction. 
Relative quantification was then assessed using the following method: 
 
Ct target = Ct control – Ct sample 
Ct Reference = Ct control – Ct sample 
 
Where: 
 
Ct target= differences between Ct values of LPAR gene 
Ct Reference= differences between Ct values of Housekeeping   gene (CANX) 
Ct Sample = threshold cycle of LPA treated cells 
Ct control = threshold cycle of untreated cells 
 
Determination of the efficiency of amplification (E) 
 
To determine the efficiency of amplification in each cycle, the slope from the standard curves 
were used to determine efficiency as shown in the equation below: 
 
E = 10(-1/slope)-1 
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Ideally this must be 100%, indicating that for every cycle the quantity of product doubled 
(E=2). Very often, however an efficiency of ≥ 90% is accepted and considered adequate. 
Once calculated the efficiency was used to determine the fold change  in  the  
exp ress ion  us ing  fo l lowing equation as shown below:  
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2.11 Statistical Evaluation 
 
All data are the means ± SE of at least 3 experiments. Statistical significance was 
performed using one-way ANOVA with post-hoc Dunnett’s test comparing with the control or 
untreated cells. Statistical differences were determined by one-way ANOVA and significance 
indicated with *p<0.05, **p<0.01, ***p<0.05. Repeated Measure Anova was carried out in 
experiment were it showed no statistical significance with one-way Anova. 
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Chapter 3 
Results 
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Chapter 3.I 
Establishment of differentiation model and 
characterization of LPA receptors 
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3.1.1 Development and characterization of P19 stem cell differentiation 
model 
The first objective of the thesis was to establish the differentiation model that could be used 
throughout the studies. The steps taken to achieve these objectives are outlined as below. 
3.1.1.1 Establishing embryoid bodies from monolayers of p19 cells 
To generate embryoid bodies (EBs), monolayers of P19 cells in culture (Figure 6) were 
routinely trypsinised and seeded in non-tissue culture grade Petri dishes in complete cell 
culture medium. Under this condition, the cells formed aggregates to form EBs in 
suspension.  This occurred within a few hours with the EBs growing in size over time but 
this was highly variable (Figure 7). 
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Figure 6. Regular growth pattern of P19 stem cells in culture. 
P19 cells were cultured in complete medium containing -minimum essential medium (-
MEM) supplemented with 10% foetal bovine serum, penicillin (100units/ml) and streptomycin 
(100g/ml) in falcon-T75 flasks and were maintained at 37oC, 95% air and 5% CO2. The 
photograph was taken under 100X magnification using an Olympus inverted microscope 2 
days after plating cells. 
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Figure 7. Formation of embryoid bodies from P19 stem cells in culture. 
Confluent monolayers of P19 cells were trypsinised and seeded 3.7 X 105 cells in non-
tissue culture grade microbiological Petri dishes in complete cell culture medium consisting 
of-minimum essential medium (-MEM) supplemented with 10% foetal bovine serum, 
penicillin (100units/ml) and streptomycin (100g/ml) and were maintained at 37
oC, 95% 
air and 5% CO2. The photographs were taken under 100X magnification using an 
Olympus inverted microscope and are representative of EBs routinely formed. 
DAY 2 DAY 3 
DAY 4 DAY 5 
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3.1.1.2 Differentiating p19 cells into cardiomyocytes using DMSO 
To ensure that P19 cells used in the studies could be differentiated, a preliminary experiment 
was conducted using DMSO, an agent known to induce stem cells differentiation (McBurney 
et al., 1982). The induction of P19 cells to differentiate into cardiomyocytes was initiated by 
treating cells with 1% DMSO during the EB forming stage. Lysates were generated at 2, 4, 6, 
8, 10 and 12 days after plating the EBs in the tissue culture grade plastics. Each lysate was 
subjected to western blotting for the cardiac-specific MLC-1v protein expression. In addition 
to detecting the latter, cells were also routinely viewed under an Olympus inverted 
microscope at 100x to look for clusters of beating cells which was taken as evidence of the 
generation of cardiomyocytes from the stem cells. These were often but not consistently 
seen in some monolayers treated with DMSO where groups of cells appear to have a 
uniform rhythm and contracted uniformly with each other. Such clusters are indicated by the 
broken circles (Figure 8). 
 
In addition to the beating cells, DMSO also induced a time-dependent increase in the 
expression of MLC-1v which was evident at day 4, increasing to a peak at day 8 to 10 but 
declining by day 12 (Figure 9). This confirms that DMSO induced the differentiation of P19 
cells into cardiomyocytes and these cells could then be used for investigating whether LPA 
can direct their differentiation into cardiac muscle cells. 
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Figure 8. DMSO-induced differentiation of P19 stem cells into beating cardiomyocytes. 
Confluent monolayer of P19 stem cell were trypsinised and seeded at a density of 3.7 X 105 
cells per dish in non-tissue culture grade microbiological Petri dishes. 1 % DMSO was added 
and embryoid bodies (EBs) allowed to form over a 4 day period. The EBs were then 
transferred into 6 well plates in DMSO-free complete culture medium. The photographs were 
taken under 100X magnification using an inverted Olympus microscope on the days shown. 
The broken circles represents where clusters of beating cells were identified following DMSO 
treatment.  
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Figure 9. DMSO induced differentiation of P19 cells into cardiomyocytes. 
P19 cells were treated with 1% DMSO during the EB formation stage and subsequently 
plated in tissue culture grade plastics as described in the Methods (section 2.3). Whole cell 
lysates were generated at the time points indicated on the graph and subjected to western 
blot analysis for MLC-1v expression. The blot shown is representative of at least 3 
independent experiments (Figure A). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data is transformed and 
presented as percentage of relative intensity of the maximum expression of MLC-1v protein 
(Figure B). Data represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. *p<0.05, **p<0.01, 
***p<0.001 when compared to the day 2 sample. 
. 
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3.1.1.3 Effect of embryoid body seeding density on the differentiation 
of P19 cells into cardiomyocytes 
In order to establish whether the seeding density of EB determined the efficiency of 
differentiation of P19 cells, EBs were formed from a predetermined number of P19 cells (3.7 
X 105 cells/petri dish) in the presence of 1% DMSO and subsequently resuspended in 12 ml 
fresh complete culture medium. Various volumes from 0.5, 0.75, 1.0, 1.5, 2.0, 2.5 ml of the 
resuspended EBs were plated into 6 well tissue culture plates. The medium was 
changed on alternative days and lysates generated on day 6. The expression of the cardiac-
specific MLC-1v protein was determined by western blotting. Figure 10 shows that 1.5, 2.0 
and 2.5 ml of the resuspended EBs were efficiently induced to differentiate into 
cardiomyocytes. In all subsequent studies, P19 cells were seeded at the same density of 
3.7 X 105 cells/petri dish and 2 ml of the resuspended EBs plated for the differentiation 
phase of the experiments. 
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Figure 10. Effects of embryoid body seeding density on the differentiation of P19 cells 
into cardiomyocytes. 
P19 cells were treated with 1% DMSO during the EB formation phase. Cells were then 
incubated for 4 days before plating in cell culture 6-well dishes as described in the in the 
Methods (section 2.3). Whole Cell lysates were generated after 6 days and subjected to 
western blot analysis for MLC-1v expression. The blot shown is representative of at least 
three independent experiments (Figure A). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed and 
presented as percentage of relative intensity of the maximum expression of MLC-1v protein 
(Figure B). Data represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data *** p<0.001 when 
compared to the 0.5ml suspension samples. 
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3.1.1.4 Effects of LPA on cell viability 
Before examining the effects of LPA on differentiation, it was important to establish whether it 
would be cytotoxic at the concentration range to be used in the studies. P19 cells were 
therefore treated with LPA at 1, 5, 10, 25 and 50M as described in the methods. As 
shown in Figure 11, there was no statistically significant difference in viability between the 
untreated cells and even the highest concentration of LPA (i.e. 50M) used suggesting that 
the compound was not cytotoxic to the cells. 
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Figure 11. Viability of P19 cells in the presence of various concentration of LPA. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with increasing 
concentrations of LPA indicated on the graph for 24 h. Cells were then incubated with MTT 
for 4 h and the MTT assay carried out after treatment as described in the Methods (section 
2.9). Data represent the mean ± S.E.M. from three independent experiments with five 
replicates in each. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. P>0.05 
confirmed there was no significant difference when compared to non-treated control. 
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3.1.1.5 LPA induced differentiation of P19 cells into cardiomyocytes 
i. Concentration-dependent effect of LPA.  
P19 cells were treated with increasing concentration of LPA (1M, 5M, 10M and 25M) at 
the EB forming stage. The EBs were subsequently plated into 6-well tissue culture plates 
on day 5. The cells were allowed to grow, changing the medium on alternative days and 
cells were lysed for western blot analysis 6 and 12 days after plating. 
 
As shown in Figure 12, at day 6 LPA induced cardiac differentiation at concentrations of 1, 
5 and 10M with 5M giving the maximum induction as evidenced by the expression of the 
cardiac-specific marker MLC-1v. At 25 M, LPA failed to induce significant induction of 
MLC-1v but it is not clear why this is especially as the cytotoxicity studies showed that LPA 
was relatively well tolerated even at concentrations of up to 50 M. Interestingly, the 
induction of MLC-1v produced by 5 M LPA was higher than that caused by DMSO which 
was used as a positive control. On day 12, all four LPA concentrations tested were able 
to induce cardiac differentiation to the same extent with no difference between 
concentrations (Figure 13).  
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Figure 12. LPA induced differentiation of P19 cells into cardiomyocytes 
P19 cells were treated with varying concentrations of LPA or 1% DMSO during the EB 
formation stage. Cells were then incubated for 4 days before plating in cell culture 6-well 
dishes as described in the Methods (section 2.4). Whole Cell lysates were generated after 6 
days of plating, and were subjected to western blot analysis for MLC-1v expression. The blot 
shown is representative of at least three independent experiments (Figure A). Respective 
band intensities were quantified by densitometric analysis and normalized to -actin protein. 
The data is transformed and presented as percentage of relative intensity of the maximum 
expression of MLC-1v protein (Figure B). Data represent the mean ± S.E.M. from three 
independent experiments. Statistical differences between means were determined using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data.*p<0.05, **p<0.01, ***p<0.001 when compared to the untreated control 
samples. 
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Figure 13. LPA induced cardiac differentiation of P19 cells.  
P19 cells were treated with varying concentrations of LPA or 1% DMSO during the EB 
formation stage. Cells were then incubated for 4 days before plating in cell culture 6-well 
dishes as described in the Methods (section 2.4). Whole Cell lysates were generated after 12 
days of plating, and were subjected to western blot analysis for MLC-1v expression. The blot 
shown is representative of at least six independent experiments (Figure A). Respective band 
intensities were quantified by densitometric analysis and normalized to -actin protein. The 
data is transformed and presented as percentage of relative intensity of the maximum 
expression of MLC-1v protein (Figure B). Data represent the mean ± S.E.M. from six 
independent experiments. Statistical differences between means were determined using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. *p<0.05, **p<0.01, when compared to the untreated control samples. 
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ii. Time-dependent induction of differentiation of P19 cells into 
cardiomyocytes by LPA. 
From the above experiments, it was confirmed that LPA induced differentiation and 5M 
was selected for time-course studies. The cells were treated with 5M LPA during the EB 
formation stage and were subsequently plated into 6 well plates. Every alternative day, the 
medium was changed and lysates were collected and analysed for MLC-1v expression by 
western blotting. As shown in Figure 14 the treatment with LPA at 5M induced 
differentiation of P19 cells from day 6 and was sustained until day 14 as evidenced by 
the expression of the cardiac-specific marker MLC-1v. In untreated cells, the basal 
expression of MLC-1v remained virtually the same from day 2 to 14. 
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Figure 14. Time dependent induction of differentiation of P19 cells by LPA. 
P19 cells were either incubated with culture medium alone control (C) or treated with 5 µM 
LPA (L) during the EB formation stage. Cells were then incubated for 4 days before plating 
in cell culture 6-well dishes as described in the Methods (section 2.4). Whole cell lysates 
were generated after 2, 6, 10 and 14 days, and were subjected to western blot analysis for 
MLC-1v expression. The blot shown is representative of at least three independent 
experiments (Figure A). Respective band intensities were quantified by densitometric 
analysis and normalized to -actin protein. The data is transformed and presented as 
percentage of relative intensity of the maximum expression of MLC-1v protein (Figure B). 
Data represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. **p<0.01, when 
compared to the untreated control samples.
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3.1.1.6 Identification of LPA receptors expressed in P19 cells. 
Following the observations made and highlighted above (section 3.1.1.5), a series of 
experiments were next initiated to identify the particular LPA receptors expressed and 
associated with differentiation following induction by LPA. Total RNA was extracted from 
a monolayer of P19 cells, reverse transcribed, and amplified by PCR using specific primers 
for the different LPAR subtypes (LPAR1-5). Sybr-Green based q-PCR analysis showing 
amplification curves for each of the receptor types identified and the housekeeping gene are 
presented in Figure 15 (A to E). A dissociation curve depicting a single curve following q-PCR 
is suggestive of product specificity in our designed assay. As shown in Figures 15 and 16, 
LPAR-1,-2,-3, and -4 were detectable whereas LPAR5 was absent (Figure 15E) from the 
total RNA analysed, suggesting that LAPR5 is not expressed by P19 cells.  
The products obtained from the RT-PCR are shown in Figure 16. The sizes of the amplicons 
detected were: LPAR1= 115 base pairs (bp), LPAR2 = 90 base pairs (bp), LPAR3 = 121 
base pairs (bp), LPAR4= 157 base pairs (bp), LPAR5 = 142 base pairs (bp). 
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Figure 15. Lysophosphatidic acid receptor expression profile in control P19 cells 
Total RNA isolated from cells was DNase treated, reversed transcribed using LPA receptor 
specific primers and subjected to PCR analysis using a Quantica Thermal Cycler as 
described in the Methods (section 2.10). Panels show dissociation curves for each receptor 
probed in control P19 cells and are representative of three individual experiments.  
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Figure 16. Lysophosphatidic acid receptor expression profile in control P19 cells. 
Total RNA isolated from cells was DNase treated, reversed transcribed using LPA receptor 
specific primers and subjected to PCR analysis using a Quantica Thermal Cycler as 
described in the Methods (section 2.10). The respective PCR products were subjected to 
agarose gel electrophoresis as described in the Methods (section 2.10). The gel is 
representative of three independent experiments. 
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3.1.1.7 Expression profile of LPA receptors in differentiated P19 cells. 
To establish whether the profile and/or levels of the receptors changed in differentiated cells, 
total RNA was isolated from controls and from LPA treated cells 6 days after plating EBs in 
the tissue culture grade 6-well plates. These were then subjected to quantitative RT-PCR 
and the levels of receptor transcripts detected normalised against the target housekeeping 
gene. The latter was initially determined by screening eight potential candidate 60s ribosomal 
protein L13a (RPL13A), ubiquitin C (UBC), beta-2-migroglobulin (B2M), glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH), beta actin (ACTB), cyclophilin (CYC), tyrosin-3-
monooxygenase/tryptophan-3-monooxygenase activation protein, zeta (YWHAZ) and 
calnexin (CANX) for stability under our experimental conditions. In these studies, comparison 
of Ct values using the Genorm software revealed that of the 8 housekeeping genes 
analysed, RPL13A was the least stable while CANX and YWHAZ were the most stable and 
the others lying in between (Figure 17). From this data, CANX was selected as the target 
housekeeping gene for normalising the levels of receptor transcripts detected. The standard 
and dissociation curves for each of the receptor analysed are shown in Figures 18, 19 and 
20.  All four LPA receptors (LPAR1-LPAR4) were present in differentiated P19 cells obtained 
6 days after LPA treatment. Each of these appear to be significantly enhanced at least at 
the mRNA level when compared to the controls non-LPA treated cells analysed in parallel. 
More importantly, of the four receptor genes, the mRNA for LPAR2 appears to be much more 
significantly enhanced, increasing by approximately 3 fold when compared to levels in 
controls (Figure 21). 
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Figure 17. Stability of housekeeping gene. 
Total RNA was isolated from cells and then DNase treated before reverse transcribing as 
described in methods using specific primers for HKGs RPL13A, UBC, B2M, GAPDH, ACTB, 
CYC, YWHAZ and CANX. The data is representative of two independent experiments. 
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Figure 18. Standard and dissociation curves for both CANX and LPA receptor 1 gene in 
P19 cells. 
Total RNA isolated from cells was DNase treated, reversed transcribed using specific primers 
and subjected to PCR analysis on a  Quantica Thermal Cycler as described in the methods. 
The panels shows: Panel 1 = cDNA standard curve for CANX; Panel 2a = cDNA standard 
curve and 2b = dissociation curve for LPAR1. The data is representative of three 
independent studies with two replicates in each. 
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Figure 19. Standard and dissociation curves for LPA receptor 2 and 3 genes in P19 
cells. 
Total RNA isolated from cells was DNase treated, reversed transcribed using specific primers 
and subjected to PCR analysis on a Quantica Thermal Cycler as described in the methods. 
The panels shows: Panel 3a = cDNA standard curve and 3b = dissociation curve for LPAR2; 
Panel 4(a) = cDNA standard curve and 4(b) = dissociation curve for LPAR3. The data is 
representative of three independent studies with two replicates in each. 
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Figure 20. Standard and dissociation curves for LPA receptor 4 gene in P19 cells. 
Total RNA isolated from cells was DNase treated, reversed transcribed using specific primers 
and subjected to PCR analysis on a Quantica Thermal Cycler as described in the methods. 
The panels show: Panel 5a = cDNA standard curve and 5b = dissociation curve for LPAR4. 
The data is representative of three independent studies with two replicates in each. 
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Figure 21. Fold change in expression of LPA receptors in LPA-induced P19 cells. 
P19 cells were either incubated with culture medium alone or treated with 5 M LPA during 
the EB formation stage. Cells were then incubated for 4 days before plating in cell culture 
6-well dishes. Total RNA isolated after 6 days was DNase treated, reversed transcribed 
using LPAR1, LPAR2, LPAR3 and LPAR4 specific primers respectively and subjected to 
PCR analysis using a Quantica Thermal Cycler as described in the Methods (section 2.10). 
The graph shows fold change in LPA receptors mRNA levels on day 6 in LPA (5M) treated 
cells normalised against CANX. The data is normalised against the housekeeping gene and 
the fold increase expressed against levels detected in non-LPA treated respective controls. 
The data represent the mean ± S.E.M. from three independent experiments with two 
replicates in each. 
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3.1.1.8 Identification of LPA receptors that mediate the differentiation 
of P19 stem cells into cardiomyocytes 
i. The role of LPAR1/3 
To investigate whether LPA-induced differentiation is mediated through LPA1/3 receptors, 
the LPA1/3 receptors antagonist Ki16425 (IC50, LPA1=0.34M, LPA2=6.5M, 
LPA3=0.93M) was used. The effect of Ki16425 on the cell viability was initially examined 
using the MTT assay as described in the methods. Ki16425 had no toxic effects on P19 cells 
except when the very high concentration of 50M was used (Figure 22). Cells were next 
treated with Ki16425 (1, 10 and 50M) for 60 min before the addition of LPA (5M) and 
lysates generated on day 6 after plating for western blotting. As shown in Figure 23, Ki16425 
inhibited LPA-induced differentiation of P19 cells in a concentration-dependent manner, 
completely abolishing MLC-1v expression at 1µM and above. This suggests that LPA-
induced cardiac differentiation is mediated, at least in part, through LPA1/3 receptors. 
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Figure 22. Viability of P19 cells in the presence of various concentrations LPA1/3 
inhibitor Ki16425. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with increasing 
concentrations of Ki16425 indicated on the graph for 24 h. Cells were then incubated with 
MTT for 4 h and the MTT assay carried out after treatment as described in the Methods 
(section 2.9). Data represent the mean ± S.E.M. from three independent experiments with five 
replicates in each. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. **denotes 
p<0.01 when compared to the untreated control samples. 
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Figure 23. Effects of Ki16425 on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), control (0.1 % 
ethanol), Ki16425 at the concentrations shown, LPA (5M) or LPA (5M) and Ki16425 
during the EB forming phase. Cells were then incubated for 4 days before plating in 
cell culture 6-well dishes as described in the Methods (section 2.5). Whole Cell lysates 
were generated after 6 days of plating, and subjected to western blot analysis for MLC-
1v expression. The blot shown is representative of at least three independent 
experiments (Figure A). Respective band intensities were quantified by densitometric 
analysis and normalized to -actin protein. The data was transformed and presented as 
percentage of relative intensity of the maximum expression of MLC-1v protein (Figure B). 
Data represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
***p<0.01, when compared to the LPA treated sample and ###p<0.01 when compared to 
the untreated sample. 
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ii. Role of LPAR4 
To investigate whether LPA-induced differentiation is mediated through the LPA4 receptor, 
the non-selective LPA4 receptor antagonist suramin was used (IC50 for purinergic receptors, 
43 M). The effect of suramin on cell viability was initially determined using the MTT assay 
as described in the methods. The results obtained revealed that suramin had no toxic 
effects on P19 cells except when a very high concentration of 1 and 5 mg/ml was used 
(Figure 24). Cells were next treated with suramin (1,5 and 50 g/ml) for 60 min before 
the addition of LPA (5M) during the EB forming stage and lysates were generated 6 days 
after plating the EBs. Changes in expression of MLC-1v were determined by western 
blotting. 
 
As shown in Figure 25 suramin inhibited LPA-induced cardiac differentiation in a 
concentration-dependent manner suggesting that LPA may act, at least in part, through 
LPA4 receptor. At the highest concentration of 50g/ml, suramin completely abolished the 
induction of differentiation to the basal level. Interestingly, suramin itself could induce the 
differentiation of P19 cells into cardiomyocytes in the absence of LPA at the very low 
concentration of 1g/ml (Figure 25). 
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Figure 24. Viability of P19 cells in the presence of suramin. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with increasing 
concentrations of suramin indicated on the graph for 24 h. Cells were then incubated with 
MTT for 4 h and the MTT assay carried out after treatment as described in the Methods 
(section 2.9). Data represent the mean ± S.E.M. from three independent experiments with 
five replicates in each. Statistical differences between means were determined using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. *p<0.05, 
*** p<0.001 when compared to the untreated control samples. 
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Figure 25. Effects of suramin on MLC-1v expression in controls and in LPA-induced 
cardiac differentiation of P19 cells. 
P19 cells were either incubated with culture medium alone (control), increasing 
concentrations of suramin, LPA (5M) or suramin with LPA (5M) during the EB 
forming phase.  Cells were then incubated for 4 days before plating in cell culture 6-
well dishes as described in the Methods (section 2.5). Whole Cell lysates were 
generated after 6 days of plating, and were subjected to western blot analysis for MLC-1v 
expression. The blot shown is representative of at least three independent experiments 
(Figure A). Respective band intensities were quantified by densitometric analysis and 
normalized to -actin protein. The data is transformed and presented as percentage of 
relative intensity of the maximum expression of MLC-1v protein (Figure B). The data 
represent the mean ± S.E.M. from three independent experiments. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) followed 
by Dunnett’s multiple comparisons test of the normalized data. **p<0.01, *p<0.05 when 
compared to the LPA treated controls and ##p<0.01 when compared to the untreated 
sample. 
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Chapter 3.II 
Role of G proteins and signalling molecules in LPA-
induced P19 stem cells differentiation
115 
 
 
 
The research carried out for this section was aimed at determining which signalling 
mechanisms may mediate the effects of LPA in our studies. Studies were therefore carried 
out investigating the role of Gi and specific signalling pathways including PI3K, Akt, PKC, 
ROCK, p38 MAPK and p42/44 MAPK which have been implicated not only in the induction 
stem cell differentiation but also linked to LPA receptor signalling in different biological 
systems. The results obtained are discussed below. 
 
3.2.1 Role of Gi in LPA-induced differentiation of P19 stem cells into 
cardiomyocytes 
To examine the involvement of Gi in the actions of LPA, pertussis toxin (PTX), a potent 
inhibitor of this G-protein was used (IC50 for PTX on ADP –ribosylation of Gi, 150 +/-
40pg/ml). The effect of PTX on cell viability was initially determined using the MTT assay 
as already described in the methods. P19 cells were treated with various concentrations of 
PTX (20,100, 200 and 1000 ng/ml) for 24h prior to the cytotoxicity assay being carried out. 
As shown in Figure 26 PTX did not cause any statistically significant change in cell viability. 
Cells were next treated with a range of concentrations of PTX (100, 200 ng/ml) for 24 
hours before the addition of LPA (5M) during the EB forming phase. Lysates were 
generated 6 days after plating the EB into tissue culture plates and used in western blotting 
to detect changes in expression of MLC-1v. In these experiments PTX at both concentrations 
of 100 and 200 ng/ml failed to inhibit the expression of MLC-1v confirming that the Gi 
may not be involved  in  the  differentiation  process  and  that  LPA  may  not  signal  
through  this molecule in inducing differentiation of P19 cells into cardiomyocytes (Figure 27). 
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Although these findings and conclusions are supported by the data, it is possible that the 
experiments may possibly be underpowered. Each study was however carried out in three 
independent experiments and although the validity of the statistical tests for underpowered 
studies may be limited, there is confidence that the trends obtained are indeed reproducible 
and consistent with both our previous work and with those of many other studies. Thus, the 
conclusions reached from the findings in this thesis would still be considered valid and 
indicative of the critical cellular events that regulate the induction of differentiation of P19 cells 
by LPA.  
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Figure 26. Viability of P19 cells in the presence of various concentrations Pertussis 
toxin in the absence and presence of LPA 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with increasing 
concentrations of PTX in the absence and presence of LPA for 24 h. Cells were then 
incubated with MTT for 4 h and the MTT assay carried out after treatment as described in 
the Methods (section 2.9). Panel (A) MTT assay for increasing concentrations of PTX alone, 
(B) MTT assay for increasing concentrations of PTX along with 5M LPA. Data represent the 
mean ± S.E.M. from three independent experiments with five replicates in each. Statistical 
differences between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test but there was no statistical significance 
between test conditions. 
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Figure 27. Effects of PTX on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), various 
concentrations of PTX alone, LPA (5M) alone, or LPA and PTX that was added 24 hours 
before LPA during the EB forming phase. Cells were then incubated for 4 days before 
plating in cell culture 6-well dishes as described in the Methods (section 2.5). Whole cell 
lysates were generated after 6 days of plating, and were subjected to western blot 
analysis for MLC-1v expression. The blot shown is representative of at least three 
independent experiments (Figure A). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed and 
presented as percentage of relative intensity of the maximum expression of MLC-1v 
protein (Figure B). Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data.  
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3.2.2 Role of PI3K in LPA-induced differentiation of P19 stem cells into 
cardiomyocytes 
In these studies, cells were treated with the potent PI3K inhibitor LY294002 ( IC5 0  = 
1.4 M) for 24 hours in the absence and presence of LPA (5M) to initially determine 
any potential cytotoxic actions of the compound.  LY294002 had no toxic effects on P19 
cells except at the high concentrations of 10M and 20M (Figure 28). In parallel 
studies, treatment of cells with LY294002 at 1, 2, 5, 10 and 20M for 60 minutes before 
the addition of LPA (5M) caused a concentration-dependent inhibition of MLC-1v 
expression (Figure 29). The inhibition was significant with 5M LY294002, which was 
found not to be cytotoxic to the cells. These findings strongly suggest an inhibition of the 
differentiation of the P19 cells into cardiomyocytes and more importantly implicates the 
PI3K pathways as being critical for this process. 
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Figure 28. Viability of P19 cells in the presence of various concentrations LY294002. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of LY294002 in the absence and presence of LPA for 24 h. 
Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of LY294002 inhibitor alone, (B) MTT assay for increasing concentrations 
of LY294002 inhibitor along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test. ***p<0.001, when compared to the controls. 
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Figure 29. Effects of LY294002 on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), various 
concentrations of LY294002 alone, LPA (5M) alone, or LPA and LY294002 during 
the EB forming phase. Cells were then incubated for 4 days before plating in cell 
culture 6-well dishes as described in the Methods (section 2.5). Whole cell lysates 
were generated after 6 days of plating, and were subjected to western blot analysis 
for MLC-1v expression. The blot shown is representative of at least three independent 
experiments (Figure A and B). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed 
and presented as percentage of relative intensity of the maximum expression of MLC-
1v protein (Figure C). Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. ***p<0.001, when compared to the LPA treated sample.  
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3.2.3 Role of Akt/Protein Kinase B (PKB) in LPA-induced 
differentiation of P19 stem cells into cardiomyocytes 
The role of Akt in LPA-induced differentiation of P19 cellls to cardiomyocytes was next 
investigated. In these studies, cells were treated with the potent Akt inhibitor, Akt inhibitor 
XIII (IC50 = 560 nM, 390 nM and 7.8 μM for Akt1, Ak2, and Akt3, respectively) for 24 
hours in the absence and presence of LPA (5M) to initially determine any potential 
cytotoxic actions of the compound. Akt inhibitor XIII had no toxic effects on P19 cells 
even at 30M (Figure 30). In parallel studies, treatment of cells with Akt inhibitor XIII at 
0.1, 0.5 and 1.0M for 60 min before the addition of LPA (5M) caused a concentration-
dependent inhibition of MLC-1v expression (Figure 31) when lysates were generated 6 
days after plating the EBs in tissue culture grade 6-well plates. The inhibition was 
significant and virtually complete with 1M Akt inhibitor XIII that was found not to be 
cytotoxic to the cells. Akt inhibitor XIII alone appeared to increase MLC-1V in a 
concentration dependent manner but these effects, although higher than basal, were 
not statistically different to controls. These findings strongly suggesting an inhibition of 
the differentiation of the P19 cells into cardiomyocytes and more importantly implicates 
the Akt pathways as being critical for this process. 
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Figure 30. Viability of P19 cells in the presence of various concentrations Akt 
inhibitor XIII. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of Akt inhibitor XIII in the absence and presence of LPA for 24 
h. Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of Akt inhibitor XIII alone, (B) MTT assay for increasing concentrations of 
Akt inhibitor XIII along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test. **p<0.01, when compared to the controls. 
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Figure 31.  Effects of Akt inhibitor XIII on LPA-induced differentiation of P19 cells 
into cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), or ranges of  
concentrations of Akt inhibitor XIII alone, LPA (5M) or LPA (5M) and Akt inhibitor 
XIII during the EB forming phase. Cells were then incubated for 4 days before 
plating in cell culture 6-well dishes as described in the Methods (section 2.5). Whole 
cell lysates were generated after 6 days of plating, and were subjected to western 
blot analysis for MLC-1v expression. The blot shown is representative of at least three 
independent experiments (Figure A). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed 
and presented as percentage of relative intensity of the maximum expression of MLC-
1v protein (Figure B). Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. 
**
p<0.01, when compared to the LPA treated sample and ##p<001, 
when compared to the untreated control.  
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3.2.4 Role of PKC in LPA-induced differentiation of P19 stem cells into 
cardiomyocytes 
In these studies, cells were treated with the potent PKC inhibitor, bisindolylmaleimide I 
(BIM-I) (IC50 = 10 nM) for 24 hours in the absence and presence of LPA (5M) to initially 
determine any potential cytotoxic actions of the compound. BIM-I is a potent competitive 
inhibitor which competes for the ATP binding site in the PKC protein. Bisindolylmaleimide 
I showed only marginal cytotoxic effects at 10 and 50 M on P19 cells (Figure 32). 
However, the morphology of the EBs with 10 and 50M concentrations of BIM-I alone 
and in presence of LPA 5M showed no differences to the EBs formed in the presence of 
lower concentrations of these compounds. In parallel studies, treatment of cells with BIM-
I at 0.1, 0.5, 1, 5 and 10M for 60 min before the addition of LPA (5M) and initiation of 
EB formation caused a concentration- dependent inhibition of MLC-1v expression (Figure 
33).  The inhibition was however significant with 5 and 10M BIM-I.  
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Figure 32. Viability of P19 cells in the presence of various concentrations 
bisindolylmaleimide I (BIM-I) 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of BIM-I in the absence and presence of LPA for 24 h. Cells 
were then incubated with MTT for 4 h and the MTT assay carried out after treatment as 
described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of BIM-I inhibitor alone, (B) MTT assay for increasing concentrations of 
BIM-I inhibitor along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test. ***p<0.001, when compared to the controls.  
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Figure  33. Effects of bisindolylmaleimide I (BIM-I) on LPA-induced differentiation of 
P19 cells into cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), or ranges of 
concentrations of BIM-I alone, LPA (5M) alone, or LPA (5M) with BIM-1 during the EB 
forming phase. Cells were then incubated for 4 days before plating in cell culture 6-
well dishes as described in the Methods (section 2.5). Whole cell lysates were 
generated after 6 days of plating, and were subjected to western blot analysis for MLC-
1v expression. The blot shown is representative of at least three independent 
experiments (Figure A and B). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed and 
presented as percentage of relative intensity of the maximum expression of MLC-1v 
protein (Figure C). Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. *p<0.05 and **p<0.01, when compared to the LPA treated sample. 
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3.2.5 Role of p38 MAPK in LPA-induced differentiation of P19 stem cells 
into cardiomyocytes 
In these studies, cells were treated with the specific competitive inhibitor of p38 MAP 
kinase, SB203580 [4-(3-Iodophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole] 
(IC50 = 34 nM) for 24 hours in the absence and presence of LPA (5M) to initially 
determine any potential cytotoxic actions of the compound (Figure 34.a). This was further 
analysed by Repeated Measured Anova and showed that there was significant 
difference between the means (P value, 0.0054) but no significant effect between 
the pairings (P value, 0.1970) (Figure 34.b). 
SB203580 is a potent competitive inhibitor which competes for the ATP binding site 
on the p38 MAPK protein (Cuenda et al.,1995). Cells were next treated with 
SB203580 (1and 10M) for 60 min before the addition of LPA (5M) during the EB 
forming phase. Lysates were generated on day 6 and used in western blotting to detect 
changes in expression of MLC-1v. In these experiments, SB203580 at both 
concentrations of 1 M and 10 M failed to inhibit the expression of MLC-1v. In fact, 
SB203580 appear to increase MLC-1v expression albeit marginally at 10 M. The data 
with this inhibitor suggests that LPA may not signal through P38 in inducing 
differentiation of P19 cells into cardiomyocytes (Figure 35). Whether SB203580 has, 
other effects that may enhance MLC-1v expression have not been investigated. 
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Figure 34. a. Viability of P19 cells in the presence of various concentrations of 
SB203580. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of SB203580 in the presence and absence of LPA for 24 h. 
Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of SB203580 inhibitor alone, (B) MTT assay for increasing concentrations 
of SB203580 inhibitor along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test.  
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Figure 34. b. Viability of P19 cells in the presence of various concentrations of 
SB203580. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of SB203580 in the presence and absence of LPA for 24 h. 
Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Data represent the mean ± S.E.M. 
from three independent experiments with five replicates in each. Statistical differences 
between means were determined using Repeated Measured ANOVA.  
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Figure 35. Effects of SB203580 on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), a range of  
concentrations of SB203580 alone, LPA (5M), or LPA (5M) and SB203580 during 
the EB forming phase. Cells were then incubated for 4 days before plating in cell 
culture 6-well dishes as described in the Methods (section 2.5). Whole cell lysates were 
generated after 6 days of plating, and were subjected to western blot analysis for MLC-
1v expression. The blot shown is representative of three independent experiments 
(Figure A). Respective band intensities were quantified by densitometric analysis and 
normalized to -actin protein. The data was transformed and presented as percentage of 
relative intensity of the maximum expression of MLC-1v protein (Figure B). Data 
represent the mean ± S.E.M. from three independent experiments. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) followed 
by Dunnett’s multiple comparisons test of the normalized data. 
 
132 
 
3.2.6 Role of ERK1/2 in LPA-induced differentiation of P19 stem cells 
into cardiomyocytes 
The other kinase signalling pathway investigated was that involving ERK1/2 (p44/p42 
MAPK). In these studies, cells were treated with the potent ERK1/2 (p44/p42 MAPK) 
inhibitor, PD98059 (Alessi et al., 1995) (IC50 = 2M) for 24 hours in the absence and 
presence of LPA (5M) to initially determine any potential cytotoxic actions of the 
compound. PD98059 had no toxic effects on P19 cells even at 50M (Figure 36). In 
parallel studies, treatment of cells with PD98059 caused a concentration-dependent 
inhibition of MLC-1v expression (Figure 37). The inhibition was significant with 
concentrations of 1M and above. These findings implicate the ERK1/2 (p44/p42 
MAPK) pathways as being critical for the LPA-induced differentiation in P19 stem cells. 
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Figure 36. Viability of P19 cells in the presence of various concentrations PD98059. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of PD98059 in the presence and absence of LPA for 24 h. 
Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of PD98059 inhibitor alone, (B) MTT assay for increasing concentrations 
of PD98059 inhibitor along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test.  
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Figure 37. Effects of PD98059 on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), a ranges of  
concentrations of PD98059 alone, LPA (5M), or LPA (5M) with PD98059 during the 
EB forming phase.  Cells were then incubated for 4 days before plating in cell culture 
6-well dishes as described in the Methods (section 2.5). Whole cell lysates were 
generated after 6 days of plating, and were subjected to western blot analysis for MLC-
1v expression. The blot shown is representative of at least three independent 
experiments (Figure A and B). Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein. The data was transformed and 
presented as percentage of relative intensity of the maximum expression of MLC-1v 
protein (Figure C). Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. ***p<0.001, when compared to the LPA treated sample. 
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3.2.7 Role of ROCK in LPA-induced differentiation of P19 stem cells 
into cardiomyocytes 
In these studies, cells were treated for 24 hours, in the absence and presence of 
LPA (5µM), with Y-27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexane 
carboxamide dihydrochloride] (IC50 = 700nM) a potent Rho-associated protein 
serine/threonine kinase (ROCK) family of protein kinases inhibitor  (Uehata et al., 
1997), to initially determine any potential cytotoxic actions of the compound (Figure 38). 
Once again these effects were marginal with the maximum decrease in MTT metabolism 
not being greater that 25%. However, these concentrations did not alter EB formation, 
which showed normal growth and development. 
 
In parallel studies, treatment of cells with Y-27632 at 10M for 60 min before the addition 
of LPA (5M) caused a concentration- dependent inhibition of LPA-induced MLC-1v 
expression (Figure 39). These findings strongly suggest a role for the ROCK in the 
differentiation of the P19 cells into cardiomyocytes. Interestingly, the inhibitor on its own 
also appears to induce differentiation of P19 cells into cardiomyocytes (Figure 39) which 
contradicts the observations showing that it inhibits the effects induced by LPA. These 
observations are unclear at the moment and require further investigation. 
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Figure 38. Viability of P19 cells in the presence of various concentrations Y-27632. 
Confluent monolayer of P19 cells were plated in 96 well plates and treated with 
increasing concentrations of Y-27632 in the presence and absence of LPA for 24 h. 
Cells were then incubated with MTT for 4 h and the MTT assay carried out after 
treatment as described in the Methods (section 2.9). Panel (A) MTT assay for increasing 
concentrations of Y-27632 inhibitor alone, (B) MTT assay for increasing concentrations 
of   Y-27632 inhibitor along with 5M LPA. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test. *p<0.05, **p<0.01 and ***p<0.001 when compared 
to the controls. 
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Figure 39. Effects of Y27632 on LPA-induced differentiation of P19 cells into 
cardiomyocytes. 
P19 cells were either incubated with culture medium alone (control), Y27632 (10M) 
alone, LPA (5M), or LPA (5M) with Y27632 (10M) during the EB forming phase.  
Cells were then incubated for 4 days before plating in cell culture 6-well dishes as 
described in the Methods (section 2.5). Whole cell lysates were generated after 6 days 
of plating, and were subjected to western blot analysis for MLC-1v expression. The 
blot shown is representative of at least three independent experiments (Figure A). 
Respective band intensities were quantified by densitometric analysis and normalized 
to -actin protein. The data was transformed and presented as percentage of relative 
intensity of the maximum expression of MLC-1v protein (Figure B). Data represent the 
mean ± S.E.M. from three independent experiments. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. ***p<0.001, when 
compared to the LPA treated sample and # # p <0 . 0 1  wh e n  c o m p a re d  to  t h e  
u n t re a t e d  co n t ro l .  
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Chapter 3.III 
LPA-induced phosphorylation of different downstream 
signalling pathway 
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Phospho-Protein studies 
The inhibitor studies reported in the previous chapter suggest that LPA may signal 
through selective protein kinase pathways. To confirm this, further experiments were 
carried out to establish whether the presence of LPA results in the phosphorylation of 
the targeted kinases. These studies were however limited to Akt, p38 MAPK and 
pERK1/2 because of time constraints and because these are amongst the kinases 
widely implicated to regulate stem cell differentiation. 
3.3.1 Time dependent phosphorylation of Akt by LPA. 
This experiment was conducted to verify the phosphorylation of Akt at 473 serine 
residue following the activation with LPA (5M). In these studies, P19 cells were 
seeded into the 35mm petri dish at a density of 2 X 104 cells/petri dish in 
complete medium. When the cells were 60-70% confluent the spent media was 
removed and replaced with fresh medium containing 1% FBS for 24 hours. After a 24-
hour period of culture in low serum, cells were treated with LPA (5M) for 0, 1, 3, 5, 
10, 15, 30, 60 and 120 minutes. After each time points, lysates were generated with 
1X lysate buffer containing phosphatase inhibitor and subjected to western blot 
analysis for phospho-Akt (Ser473). Figure 40 show that LPA induces Akt 
phosphorylation that was evident at 5 min and sustained for up to 1 hour after 
treatment. 
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Figure 40. Time course of Akt phosphorylation induced by LPA. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and 
cultured in medium consisting of -MEM supplemented with 1% FBS, 
100units/ml penicillin/100g/ml streptomycin. Cells were incubated for specific 
time points with LPA (5M); lysates generated and subjected to western blot 
analysis for phospho-Akt (Ser473) expression. The blot shown is representative 
of at least three independent experiments (Figure A). Respective band intensities 
were quantified by densitometric analysis and normalized to -actin protein. The 
data was transformed and presented as percentage of relative intensity of the 
maximum expression of phospho-Akt (Ser473) (Figure B). Data represent the 
mean ± S.E.M. from three independent experiments. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. 
*p<0.05when compared to the untreated control samples. 
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3.3.2 Time dependent phosphorylation of ERK1/2 by LPA. 
This experiment was conducted to verify the phosphorylation of p-ERK1/2 
(Thr202/Tyr204) residue following the activation with LPA (5M). The experiments 
were set up as described previously and then activated with LPA (5M) for 0, 1, 3, 5, 
10, 15, 30, and 60 minutes. Lysates generated were subjected to western blotting for 
p-ERK1/2 (Thr202/Tyr204). Figure 41 shows that LPA induces ERK1/2 
phosphorylation, which was evident at the very early time point of 3 min and rapidly 
declining from 5 minutes becoming barely detectable 10 minutes after LPA treatment. 
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Figure 41. Time course of ERK1/2 phosphorylation induced by LPA. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and 
cultured in medium consisting of -MEM supplemented with 1% FBS, 
100units/ml penicillin/100g/ml streptomycin. Cells were incubated for specific 
time points with LPA (5M), lysates were generated and subjected to western 
blot analysis for phosph-ERK1/2(Thr202/Tyr204) expression. The blot shown is 
representative of at least three independent experiments (Figure A). Respective 
band intensities were quantified by densitometric analysis and normalized to -
actin protein. The data was transformed and presented as percentage of relative 
intensity of the maximum expression of phosph-ERK1/2(Thr202/Tyr204) (Figure 
B). Data represent the mean ± S.E.M. from three independent experiments. 
Statistical differences between means were determined using one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. ***p<0.001, when compared to the untreated control samples. 
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3.3.3 Time dependent phosphorylation of p38 MAPK by LPA. 
To establish whether LPA induced P38 phosphorylation, lysates were generated as 
described for the other studies following treatment with LPA (5M) for 0, 1, 3, 5, 10, 15, 
30, and 60 minutes. Western blot analysis was conducted for phospho-p38MAPK. 
Figure 42 show that LPA induces p38- MAPK phosphorylation, which was evident at 3 
min and sustained for up to 30 minutes but declining 1 hour after LPA treatment. 
144   
 
Con 1 3 5 10 15 30 60
0
25
50
75
100
125
150 *
A
B
        minutes
p
3
8
 M
A
P

%
 A
c
ti
v
a
ti
o
n
 w
it
h
 5

M
 L
P
A
 
Figure 42. Time course of p38 MAPK phosphorylation induced by LPA. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated for specific time points with LPA 
(5M), lysates were generated and subjected to western blot analysis for Phospho-p38 
MAPK expression. The blot shown is representative of at least three independent 
experiments (Figure A). Respective band intensities were quantified by densitometric 
analysis and normalized to -actin protein. The data was transformed and presented as 
percentage of relative intensity of the maximum expression of Phospho-p38 MAPK 
(Figure B). Data represent the mean ± S.E.M. from three independent experiments. 
Statistical differences between means were determined using one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons test of the normalized 
data. *p<0.05, when compared to the untreated control samples. 
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3.3.4 Effects of suramin and Ki16452 on LPA-induced Akt 
phosphorylation  
To establish whether the effects of suramin (LPAR4 inhibitor) and Ki16425 (LPAR1/3 
inhibitor) reported earlier are linked to the regulation of Akt phosphorylation, P19 cells 
were treated with 50g/ml or 10 M concentrations of these inhibitors respectively prior 
to activation with 5 M LPA for 15 min. Lysates generated were analysed by western 
blotting for AKT phosphorylation. Figure 43 shows that LPA induced Akt 
phosphorylation was not inhibited by either suramin or Ki16425 suggesting that neither 
inhibitor regulated LPA-induced differentiation of P19 cells through suppression of Akt 
activation. 
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Figure 43. Effects of Suramin and Ki16425 on LPA-induced Akt-phosphorylation. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of Ki16425 or suramin. The latter were added 60 minutes 
before the addition of LPA for a further 15 minutes; lysates were generated, and were 
subjected to western blot analysis for phospho-Akt (Ser473) expression. The blot 
shown is representative of at least three independent experiments (Figure A). 
Respective band intensities were quantified by densitometric analysis and normalized to 
-actin protein. The data was transformed and presented as percentage of relative 
intensity of the maximum expression of Phospho-p38 MAPK (Figure B). Data represent 
the mean ± S.E.M. from three independent experiments. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data but showed no statistical 
difference between treatments.  
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3.3.5 Effects of Suramin and Ki16452 on LPA induced 
phosphorylation of ERK1/2 (p42/44 MAPK) 
In addition to investigating Akt, parallel experiments were also carried out to establish 
whether the effects of suramin (LPAR4 inhibitor) and Ki16425 (LPAR1/3 inhibitor) 
reported earlier are linked to the regulation of ERK1/2 (Thr202/Tyr204) 
phosphorylation. P19 cells were therefore treated with either 50g/ml suramin or 10 M 
Ki16425 prior to activation with 5 M LPA for 3 minutes. Lysates generated were 
analysed by western blotting for phospho-ERK1/2 (Thr202/Tyr204). Figure 44 shows 
that LPA induced ERK1/2 phosphorylation was completely abolished by both receptor 
antagonists indicating that, unlike Akt, phosphorylation of ERK1/2 by LPA may be 
mediated via the activation of LPAR1/3 and potentially LPAR4. 
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Figure 44. Effects of Suramin and Ki16425 on of ERK1/2 (Thr202/Tyr204) -
phosphorylation in the differentiation of P19 cells into cardiomyocytes. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of Ki16425 or suramin. The latter were added 60 minutes 
before the addition of LPA for a further 3 minutes; lysates were generated, and were 
subjected to western blot analysis for Phospho- ERK1/2 (Thr202/Tyr204) expression. 
The blot shown is representative of at least three independent experiments (Figure A). 
Respective band intensities were quantified by densitometric analysis and normalized to 
-actin protein. The data was transformed and presented as percentage of relative 
intensity of the maximum expression of Phospho- ERK1/2 (Thr202/Tyr204) (Figure B). 
Data represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
***p<0.001 when compared to the LPA treated samples.  
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3.3.6 Effects of Suramin and Ki16452 on LPA-induced 
phosphorylation of p38 MAPK  
Following on from the studies above, experiments were also carried out to establish 
whether the effects of suramin (LPAR4 inhibitor) and Ki16425 (LPAR1/3 inhibitor) 
reported earlier are linked to the regulation of p38 MAPK phosphorylation. P19 cells 
were therefore treated with 50g/ml suramin or 10 M Ki16425 prior to activation with 5 
M LPA for 10 minutes. Lysates generated were analysed by western blotting for 
phospho-p38 MAPK. Figure 45 shows that LPA induced p38 MAPK phosphorylation 
was also inhibited by suramin and by Ki16425, with both compounds abolishing 
expression of the phosphorylated protein.  Interestingly, inhibition of P38 with 
SB203580 did not suppress differentiation and even appeared to enhance the latter. 
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Figure 45. Effects of Suramin and Ki16425 on p38 MAPK-phosphorylation in the 
differentiation of P19 cells into cardiomyocytes. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of Ki16425 or suramin. The latter were added 60 minutes 
before the addition of LPA for a further 10 minutes; lysates were generated, and were 
subjected to western blot analysis for Phospho-p38 MAPK expression. The blot shown 
is representative of at least three independent experiments (Figure A). Respective band 
intensities were quantified by densitometric analysis and normalized to -actin protein. 
The data was transformed and presented as percentage of relative intensity of the 
maximum expression of Phospho-p38 MAPK (Figure B). Data represent the mean ± 
S.E.M. from three independent experiments. Statistical differences between means 
were determined using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test of the normalized data. ***p<0.001 when compared to the 
LPA treated samples. 
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3.3.7 Crosstalk signalling study 
It is widely accepted that there may be crosstalk between cell signalling molecules, with 
the activation of one pathway resulting in the subsequent regulation of another. Thus, 
because of the diverse range of signalling proteins identified above as potentially being 
associated with the effects of LPA, additional studies were carried out to establish 
whether there was indeed crosstalk between the kinase pathways identified.   
3.3.7.1 Crosstalk between other kinases and the Akt pathway 
In these studies, experiments were conducted to examine the effects of LY294002 
(5M), BIM-I (10M), PD98059 (5M), ROCK (10M), Akt inhibitor XIII (1M), and 
SB203580 (10M) on Akt phosphorylation by LPA (5M). After a 24-hour period of 
culture in low serum, cells were incubated in medium containing 1% FBS with 
appropriate concentrations of the selected kinase inhibitors for 60 minutes. These were 
then challenged with 5 M LPA for 15 minutes. Lysates were generated and 
subjected to western blotting for AKT phosphorylation using specific antibody. Figure 
46 shows that LPA induced Akt phosphorylation at 15 minutes; however, none of the 
kinase inhibitors used significantly altered LPA-induced phosphorylation of AKT at ser-
473.  
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Figure 46. Regulation of LPA induced Akt-phosphorylation at Serine 473 residue 
by various kinase inhibitors 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of LY294002 (5M), BIM-I (10M), PD98059 (5M), ROCK 
(10M), Akt inhibitor XIII (1M), and SB203580 (10M). The latter were added 60 
minutes before the addition of LPA for a further 15 minutes; lysates were generated, 
and were subjected to western blot analysis for phospho-Akt (Ser473) expression. The 
blot shown is representative of at least three independent experiments (Figure A). 
Respective band intensities were quantified by densitometric analysis and normalized to 
-actin protein. The data was transformed and presented as percentage of relative 
intensity of the maximum expression of phospho-Akt (Ser473) (Figure B). Data 
represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
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3.3.7.2 Crosstalk between other kinases and the ERK1/2 pathway 
In these studies, experiments were conducted to examine the effects of LY294002 
(5M), BIM-I (10M), PD98059 (5M), ROCK (10M), Akt inhibitor XIII (1M), and 
SB203580 (10M) on the activation of ERK1/2 (Thr202/Tyr204) phosphorylation.  The 
experiments were setup as described previously and subsequently incubated with 5 
M LPA for 3 minutes. Lysates were generated and western blotting conducted for 
ERK1/2 (Thr202/Tyr204 phosphorylation using specific antibody. Figure 47 show that 
LPA induced ERK 1/2 phosphorylation was significantly inhibited by LY294002, BIM, 
PD98059, Y27632 and Akt inhibitor XIII, which completely abolish the activation of 
ERK1/2 by inhibiting its phosphorylation at Thr202/Tyr204. Interestingly, SB203580 
failed to inhibit the activation of ERK1/2. 
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Figure 47. Regulation of LPA induced ERK1/2 (Thr202/Tyr204)-phosphorylation by 
various kinase inhibitors. 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of LY294002 (5M), BIM-I (10M), PD98059 (5M), ROCK 
(10M), Akt inhibitor XIII (1M), and SB203580 (10M). The latter were added 60 
minutes before the addition of LPA for a further 3 minutes; lysates were generated, 
and were subjected to western blot analysis for Phospho- ERK1/2 (Thr202/Tyr204) 
expression. The blot shown is representative of at least three independent experiments 
(Figure A). Respective band intensities were quantified by densitometric analysis and 
normalized to -actin protein. The data was transformed and presented as percentage 
of relative intensity of the maximum expression of Phospho- ERK1/2 (Thr202/Tyr204) 
(Figure B). Data represent the mean ± S.E.M. from three independent experiments. 
Statistical differences between means were determined using one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons test of the normalized 
data. **p<0.01 when compared to the 5M LPA samples. 
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3.3.7.3 Crosstalk between other kinases and the P38 pathway 
In parallel to those above, experiments were also conducted to examine the effects of 
of LY294002 (5M), BIM-I (10M), PD98059 (5M), ROCK (10M), Akt inhibitor XIII 
(1M), and SB203580 (10M) on the activation of p38 MAPK through phosphorylation. 
The experiments were setup as described previously and subsequently incubated with 
5 M LPA for 10 minutes. Figure 48 shows that LPA induced p38 MAPK 
phosphorylation was inhibited by LY294002 and Y27632 but not by SB203580, Akt 
inhibitor XIII or PD98059. The inhibition cause by BIM although pronounced, was not 
statistically significant when compared to LPA 5M. 
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Figure 48. Regulation of LPA induced p38 MAPK- phosphorylation by various 
kinase inhibitors 
Confluent monolayers of P19 cells were plated in 35mm petri dishes and cultured in 
medium consisting of -MEM supplemented with 1% FBS, 100units/ml 
penicillin/100g/ml streptomycin. Cells were incubated with or without LPA (5M) in 
the absence and presence of LY294002 (5M), BIM-I (10M), PD98059 (5M), ROCK 
(10M), Akt inhibitor XIII (1M), and SB203580 (10M). The latter were added 60 
minutes before the addition of LPA for a further 10 minutes as described in the 
Methods (section 2.6).  Whole cell lysates were generated, and were subjected to 
western blot analysis for Phospho-p38 MAPK expression. The blot shown is 
representative of at least three independent experiments (Figure A). Respective band 
intensities were quantified by densitometric analysis and normalized to -actin protein. 
The data was transformed and presented as percentage of relative intensity of the 
maximum expression of Phospho-p38 MAPK (Figure B). Data represent the mean ± 
S.E.M. from three independent experiments. Statistical differences between means 
were determined using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test of the normalized data. *p<0.05, ***p<0.001 when compared 
to the 5M LPA samples.  
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Key Findings 
 Data confirms that LPA caused induction of differentiation of P19 stem cells into 
cardiomyocytes at physiological concentrations. 
 P19 stem cells expressed LPA receptors 1 to 4. 
 The LPA induced differentiation of P19 cells into cardiomyocytes through LPA 
receptors 1/3 and 4. LPAR2 was not investigated because of the lack of 
commercially available inhibitors.  
 The induction of differentiation by LPA may be coupled to downstream signalling 
pathways, which include ROCK, PI3K, PKC and/or Akt and may converge on 
ERK1/2. Inhibition of any of these pathways has the potential to suppress 
differentiation.  
 In contrast, signalling leading to P38 activation may potentially suppress the 
process but this needs further clarification. 
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Figure 49. Regulation of P19 stem cells differentiation into cardiomyocytes.  
LPA induces differentiation of P19 stem cells into cardiomyocytes potentially through 
ERK1/2. PI3K, ROCK and PKC are proposed as upstream pathways that activate 
MEK1/2 and stimulate ERK1/2. These PTX-insensitive pathways are 
Gq11/G12/13/Gcoupled.  
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Chapter 4 
Discussion 
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It is estimated that around two million people across the UK are affected with coronary 
heart disease and it still remains the major cause of death across the world. The only 
promising and effective treatment for this disease is heart transplantation. It is identified 
that stem cells could be effectively used in regenerative medicine and have the 
potential to regenerate infarcted myocardium, which could be an alternative treatment 
for coronary heart diseases.  
 
Currently, stem cell differentiation can be induced experimentally using growth factors, 
hormones, solvents and chemicals such as dimethyl sulphoxide (Skerjanc, 1999) or 5-
azacytidine (Rangappa et al., 2003). Despite the successes with these agents, most 
are not physiological and cannot be used in translational therapy because of the 
toxicity or unwanted effects associated with such chemicals. As a result there has 
been great interest and some progress in identifying more physiologically relevant 
molecules. In this regard, it has been reported that hormones like oxytocin and other 
molecules like retinoic acid induce differentiation of mouse embryonic stem cells into 
cardiomyocytes (Bugorsky et al., 2009). In addition, Wnt and BMPs are active 
modulators of differentiation of human pluripotent stem cells into cardiomyocytes (Lian 
et al., 2012) and growth factors like fibroblast growth factors (FGF-2) stimulate the 
differentiation of neural stem cells (Hienola et al., 2004).  
 
The studies reported in this thesis have extended current findings on physiological 
regulators of stem cell differentiation by focusing on identifying the role of LPA in the 
induction of differentiation of P19 cells into cardiomyocytes.  
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Lysophosphatidic acid is an interesting molecule because although it has been 
implicated in disease states, for instance contributing to  endothelial permeability 
and stress fiber formation during early atherosclerotic lesion formation (Colangelo  et 
al., 1998; Ross, 1993). it also elicits various biological functions such as triggering 
neuronal differentiation of cortical neuroblasts and induces proliferation (Fukushima et 
al., 2007). In addition, LPA has also been reported to exert anti-apoptotic actions on 
mesenchymal stem cells, which may aid in facilitating their survival within the 
ischaemic myocardium (Karliner, 2004; Chen et al., 2008). A closely related 
phospholipid, sphingosylphosphorylcholine (SPC) has also been reported to induce 
differentiation of mouse embryonic stem cells in to cardiomyocytes suggesting that 
biolipids such as LPA can  potentially regulate stem cell differentiation in vivo. Few 
reports have also suggested a role for LPA in  blood  and  lymphatic  vessel  formation  
during  embryogenesis  (Sumida  et  al., 2010). It has also recently been shown to 
induce differentiation of rat embryonic stem cells but into neuroglial and cholinergic 
neurons (Cui et al., 2006). However, there are no reports on the ability of LPA to 
generate cardiomyocytes from stem cells. This has therefore been the focus of this 
thesis that is aimed at investigating the effect of LPA on the ability of stem cells to 
differentiate into cardiomyocytes. 
 
In our studies, we have used P19 stem cell line for conducting all of our experimental 
studies. P19 cells are relatively easy to culture and can be maintained in the 
undifferentiated state without the need for factors such as leukemia inhibitory factor 
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(LIF) or feeder layer, and provide a good model for differentiation of stem cells into 
cardiomyocytes. The protocols are also well established (Paquin et al., 2002; van der 
Heyden et al., 2003; Wobus et al., 1991) and have demonstrated the expression of 
cardiac transcription factors and specific cardiac protein in the differentiated P19 cells 
similar to other cardiac lineage-committed cells (Grepin et al., 1997; Maltsev et al., 
1993; Monzen et al., 1999; Skerjanc, 1999). Moreover, they have also demonstrated 
that P19 cells undergo a similar process of the cardiac developmental stages during 
embryogenesis and express cardiac markers such as Nkx2.5, GATA-4, cardiac 
specific proteins like MHC, Troponin I and MLC (Habara-Ohkubo, 1996;Monzen et 
al., 1999).  
 
DMSO can induce P19 cells to differentiate into cardiomyocytes in part by the induction 
of the canonical Wnt/-catenin signalling molecules (Nakamura et al., 2003). 
Epigenetic studies have also shown the upregulation of DNA methyl transferase 3a 
and histone modification on exposure to DMSO (Iwatani et al., 2006). Similarly, 
treatment of P19 cells with DMSO causes the expression of the alpha and beta- 
cardiac MHC along with sarcomere MHC and MLC (Habara-Ohkubo, 1996; Moore et 
al., 2004). These findings indicate that DMSO may be a good inducer of the 
differentiation of embryonic carcinoma cells into cardiomyocytes and has therefore 
been used in our studies as a positive control for the differentiation process.  
 
The formation of 3-dimensional EBs is considered vital for the induction of 
differentiation of embryonic stem cells (Desbaillets et al., 2000; Grover et al., 1983). 
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Thus, in all our studies, P19 stem cells were initially plated into petri dishes during 
which they formed a 3-dimensional embryoid body with varying shapes and sizes, and 
with the cell mass formed expressing markers characteristic of the ectoderm, 
endoderm and mesoderm layers similar to that seen during the embryogenesis.  On 
transferring these EBs to a tissue culture grade plate the adhered and formed 
monolayer of cells. Cells treated with 1% DMSO showed differentiation into 
cardiomyocytes from day 4 with beating clusters of cells from day 6-7 and sustained 
until day 12. The addition of LPA also induced differentiation of P19-derived EBs into 
cardiomyocytes. This effect was both time and concentration dependent and support 
studies with SPC, which have been reported to induce differentiation of mouse 
embryonic stem cells to cardiomyocytes. 
 
The normal concentration of LPA in serum ranges between 1 and 5M, but 
concentrations can reach up to 20M when generated by activated platelets in the 
circulation (Baker et al., 2002; Eichholtz et al., 1993; Sano et al., 2002). In our studies, 
LPA showed a bell-shaped response with 5M inducing optimum differentiation and 
this is well within the physiological range. As a result, all subsequent experiments were 
carried out using 5M LPA, which was also found not to exert any cytotoxic effects on 
cells. Interestingly at the higher concentrations where differentiation was 
suppressed (eg 25M) LPA was shown to have marginal toxicity and this may 
account for the effects observed at these high concentrations. The concentration of 
5M is however consistent with previous studies which were carried out at a range of 
1-10M LPA (Fukushima et al., 2007; Cui et al., 2007).The differentiation of P19 cells 
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to cardiomyocytes induced by LPA was confirmed by the presence of beating clusters 
of cells and by western blotting probing for MLC-1v. Both these markers were evident 
on day 6 after plating EBs into tissue culture dishes and allowed to grow into 
monolayers. Interestingly, on day12, all the four concentrations (1, 5, 10 and 25M) of 
LPA used could induce differentiation to the same extent and these were comparable 
to the induction of differentiation by 1% DMSO. In parallel to the above experiment, 
time course studies with 5M LPA showed differentiation was time dependent with a 
significant increase in differentiation and sustained until day 14.  
 
Further experiments were conducted to identify the LPA receptors that may be crucial 
for differentiation of P19 cells into cardiomyocytes. All the LPA receptors belong to the 
family of seven transmembrane spanning G protein-coupled receptors (GPCRs). LPA 
has been reported as a ligand for the ventricularzone-1 receptor identified and isolated 
from mouse complementary deoxyribonucleic acid (cDNA) (Hecht et al., 1996). 
LPAR1-3 are members of the endothelial differentiation gene (Edg) family (Mutoh et 
al., 2008; Virag et al., 2003). These three members share 45-56% overall amino acid 
identity. Recently used nomenclature for LPA receptors are LPA1 (Edg-2), LPA2 (Edg-
4), and LPA3 (Edg-7) and are in accordance with the guidelines of the International 
Union of Pharmacology (Contos et al., 2002; Wang et al., 2001). The newly identified 
receptors include    LPA4/P2Y9/GPR23, LPA5/GPR92 (Lee et al., 2007), and LPA6 
(GPR87) (Ye, 2008). These receptors are also coupled to G-proteins such as G12/13, 
Gi/o, Gq, and probably other G proteins except Gs (Contos et al., 2000). 
Moreover, all these receptors show distinct tissue distribution in the body. In relation to 
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stem cells, LPA receptors 1, 2 and 3 have been shown to be expressed in mouse 
embryonic stem cells, LPAR1 has also been shown to be present in mesenchymal 
stem cells and all 5 receptors are present in neuronal progenitor cells (Chen et al., 
2008; Dubin et al., 2010; Todorova et al., 2009;). 
 
Studies to determine the expression of LPA trans-membrane receptor expression 
profile in the P19 cells was carried out by reverse transcription and real time-PCR 
analysis of total mRNA from control non induced cells using the relative quantification 
method with cDNA standards (Pfaffl, 2001). This method is now routine and very 
sensitive as well as reproducible, permitting the quantification of transcripts with very 
high accuracy (Yuen et al., 2002). A housekeeping gene (HKG) was used to 
standardise the data. Housekeeping genes are expressed in all cells and are required 
for the normal maintenance of cellular function both in normal and pathophysiological 
conditions. While a few genes like GAPDH, HSP90 and-actin can remain unaltered 
other HKGs may be altered by various experimental condition.  It is therefore 
important to discover authentic HKGs for analysis in a specific experimental condition 
to ensure that the its expression levels are not altered by the treatment. In our 
studies, the normalization was conducted using 8 HKGs, and Calnexin and tyrosine 
3- monooxygenase/tryptophan 5-monooxygenase activation protein. Calnexin is an 
integral protein which acts as a chaperone and important for protein folding. YWHAZ is 
a protein which has been indicated to function in the regulation of insulin sensitivity. 
Calnexin was found to be the most stable under our experimental condition and 
therefore used as the housekeeping gene for normalizing changes in LPA receptor 
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expression.   
The single product of the PCR amplicon that is crucial in these studies was confirmed 
using two principles. Firstly, the presence of a single peak in all PCR runs and 
secondly the separation of the amplicon based on amplicon size using a DNA ladder 
(50 base pairs). The agarose gel electrophoresis (2%) conducted with the DNA 
amplicons from the real time PCR showed the expression of LPA receptors 1, 2, 3, and 
4 but not receptor 5. This confirms that P19 cells express LPA receptors 1-4 and not 5, 
hence these receptors could be involved in the differentiation to cardiomyocytes. This 
result is consistent with the previous report that has shown the involvement of LPA in 
the proliferation of P19 cells through cAMP response element binding protein, CREB 
(Kim et al., 2012). What is more interesting is the observation that when P19 cells were 
treated with LPA, upon differentiation, express higher levels of transcripts for the 
LPA receptors when compared to controls. Even more interesting is the observation 
that LPAR2 was increased by up to 3 fold under these conditions. This finding 
suggests that LPAR2 could be a potentially critical LPA receptor in P19 stem cell 
derived cardiomyocytes.  This is the first report to show this profile of change in these 
receptors especially when stem cells are compared to the differentiated cells that have 
originated from them. The relevance of this finding however remains to be determined 
in full.  
 
To identify which receptor may be associated with the induction of differentiation by 
LPA, studies were conducted using known pharmacological inhibitors of LPAR1/3 and 
LPAR4. To determine the role of LPAR1/3 the antagonist Ki16425 was used as this 
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has been reported to be selective for these receptors (Ohta et al., 2003). It has a 
molecular formula of C23H23ClN2O5S and molecular weight of 474.96 kDa. Studies 
have shown it to cause complete inhibition in Ca2+rise observed during the LPA 
induced osteoblastic differentiation of human mesenchymal stem cells when used at a 
concentration of 10M. It is also reported to inhibit neuronal differentiation of human 
embryonic stem cells at the same concentration (Dottori et al., 2008). Thus, for our 
experiments Ki16425 was used at a range of concentrations of 1, 10 and 50M. The 
result demonstrated that Ki16425 concentration dependently inhibited the expression 
of MLC-1v with 10 M virtually abolishing the latter.  These results suggest that 
LPAR1 and/or 3 may be involved in the LPA mediated effects in inducing P19 cells 
differentiation into cardiomyocytes. We cannot howe ve r  rule out that the effect 
may in fact only involve one or the other rather than both receptors but until selective 
inhibitors are available which can distinguish between LPAR1 and LPAR3 we cannot 
conclude which is the critical target for the actions of LPA. The implication of these 
receptors in the differentiation process however fits with at least one other study, which 
has shown that LPAR1/3 may be involved in neuronal differentiation and in the anti-
apoptotic mechanisms associated with LPA (Chen et al., 2008; Fukushima et al., 
2007). 
 
P19 cells express LPAR1-4 and the other receptors not blocked by Ki16425 may in 
fact be critical for the differentiation process. To address this, a further study was 
carried out using the non-selective antagonist of LPAR4, suramin.This is a 
polysulphonated naphthylurea with a molecular mass of 1297.29 kDa, which shows 
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diverse biological effects and antagonises the P2Y receptors. LPAR4 shows a closer 
identity towards the P2Y receptor than the Edg family of receptors (20-24 %) 
(Yanagida et al., 2007). Reported studies have revealed the inhibitory action brought 
about by suramin on LPA-induced effect is mediated through GPCR (van Corven et 
al., 1992; van der Bend et al., 1992). When used in our studies, experiments were 
conducted initially with 0.05, 0.1 and 0.5 mg/ml concentrations of suramin. All these 
three concentrations showed complete inhibition of the differentiation of stem cells 
induced by LPA. Further experiments were conducted with lower concentrations of 
0.001 and 0.005 along with 0.05 mg/ml. A dose dependent response was observed 
and showed inhibitions back to control levels with 0.05 mg/ml with no significant 
inhibition at lower concentrations. This demonstrates the involvement of LPAR4 
receptor in the LPA induced differentiation of P19 cells. 
 
Interestingly, it was observed that suramin alone induced differentiation at 0.001mg/ml 
concentration. This is unexpected and requires further investigation. However in 
addition to inhibiting P2Y receptors, suramin has been reported to elicit many more 
biological roles like blocking the binding of various growth factors to their receptors 
(Hosang, 1985; Coffey et al., 1987), inducing differentiation of mouse embryonic stem 
cells to sinus nodal like cells (Wiese et al., 2011). The precise mechanism that 
underlies the direct induction by suramin of the differentiation of P19 cells into 
cardiomyocytes is currently unclear but its ability to induced differentiation of mouse 
embryonic stem cells to sinus nodal like cells is reported to occur through Ryanodine 
receptor. Whether this is the case in the P19 cells remains to be established. 
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Following the observations that LPA can induce the differentiation of p19 cells into 
cardiomyocytes and establishing that this effect is mediated through known LPA 
receptors, the next phase of the studies embarked on identifying the signalling 
mechanisms that may mediate the actions of LPA. Many reports have claimed that the 
LPA effects may be mediated through PTX sensitive and insensitive pathways which 
induce calcium mobilisation, gene transcription, MAPK stimulation, DNA synthesis, and 
cytoskeletal changes (Bandoh et al., 1999; Fukushima et al., 1998; Weiner et al., 
1999). For example, LPAR1 triggered survival of rat Schwann cells and proliferation of 
oligo-dendrocytes are mediated through PTX-sensitive Gi/o/PI3K/Akt signalling 
pathways (Weiner et al., 1999). Similarly, LPA triggered DNA synthesis has been 
shown to differ in its PTX-responsive effects in that there may be a PTX sensitive and 
a PTX insensitive component to the response (Tabuchi et al., 2000; Keller et al., 
1997). In addition, LPA inhibiting hESCs differentiation to neuronal progenitor was also 
reported to occur through a PTX-insensitive pathway (Dottori et al., 2008). The 
divergence in the PTX sensitivity shown in the previous studies may be because of 
variations in the species, origin, developmental phases, and/or culture prerequisite. 
Gi subunit is ADP-ribosylated by PTX there by leaving it in inactive state. This further 
inhibit the signalling events mediated through cAMP (Burns, 1988). To determine 
whether responses to LPA in our studies are PTX sensitive, experiments were 
conducted using PTX to inhibit LPA-induced differentiation of P19 cells. Our data 
revealed that PTX was without effect even though we used pharmacological 
concentrations, which have previously been used in other studies conducted in MSCs 
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and hESCs (Chen et al., 2008; Kim et al., 2005). This clearly reveals that the LPA 
induced differentiation to cardiomyocytes is not coupled to the PTX-sensitive Gi 
signalling. Currently it is not clear whether the other G protein subunits including Gq, 
G12/13 or G are involved but it is likely that at least one of these will be part of the 
LPA receptor signalling process. Currently there are no commercially available 
inhibitors for these proteins and studies that have looked at their involvement have 
used a transfection approach which is currently beyond the scope of this thesis 
because of time constraints. 
 
It is likely that any physiological actions are channelled through multiple signalling 
pathways. This is crucial and expected when a particular cell system shows multiple 
receptor expression similar to our study. To identify the upstream signalling, 
additional experiments were conducted focusing on kinase pathways including the 
mitogen activated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K), 
Akt/protein kinase B (PKB), protein kinase C (PKC), Rho- associated protein kinase 
(ROCK). 
 
Initial experiments examined the effects of PI3K pathway in the regulation of 
differentiation of P19 cells with 5M LPA. The role of PI3K pathway has been 
extensively studied in many cell systems and it has been reported to play a crucial role 
in many physiological functions (Bekhite et al., 2011; Okkenhaug et al., 2003). A 
previous study has reported the role of PI3K signalling in the induction of differentiation 
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of mESC into cardiomyocytes induced by Neuregulin-1and this was shown to involve 
the activation of cAMP Response Element Binding Protein (CREB) (Okkenhaug et al., 
2003). PI3K is also reported to be involved in LPA induced proliferation of rat 
chondrocytes and Schwann cells (Kim et al., 2005; Li et al., 2003). In addition, PI3K 
promotes the differentiation of cardiac derived stem cells into vascular endothelial cells 
mediated by Vascular Endothelial Growth Factors (VEGF) (Xiao et al., 2013). In studies 
like differentiation of hESC into endothelial cells are mediated through the PI3K 
signalling pathway (Merkely et al., 2014). Thus we conducted experiments using 
LY294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one], a  potent inhibitor of 
P I 3 K . This compound acts by binding at the ATP-binding site of the enzyme (Vlahos 
et al., 1994) and is a specific inhibitor that does not show inhibition on the other 
Kinases like, Lipid Kinases, Serine/Threonine Kinases or Protein Tyrosine Kinases. In 
these studies, LY294002 was used at a range of concentrations from 1-20M. This 
was based on published literature reporting the various concentration ranges of 
LY294002 showing inhibitory effects on various cellular systems (Pong et al., 1998; 
Watanabe et al., 2008; Xiao et al., 2013). The data obtained showed that LY294002 
significantly inhibited the differentiation of P19 cells into cardiomyocytes, strongly 
implicating the PI3K signalling pathways as being critical for this process and was only 
cytotoxic at 20M. These findings are consistent with other reports, which have 
indicated that treatment with LY294002 inhibited differentiation of ES to 
cardiomyocytes, and showed EBs to have reduced beating foci (Klinz et al., 1999).  
 
The downstream target of PI3K signalling is Akt and, although this has not been 
172   
 
 
established yet in our studies, these two form a cascade that feeds into the nucleus 
to trigger differentiation. In this regard, it is worth noting that other reports have 
suggested effects of LPA may be mediated through PI3/Akt signalling. For instance, 
activation of the PI3K/Akt signalling pathway by LPA in Caco-2 colon cancer cells 
protects these cells from apoptosis (Rusovici et al., 2007). Furthermore, the same 
pathway activated by LPA inhibits migration of MDA-MB-231 breast cancer cells (Du et 
al., 2010).  Thus, the PI3K/Akt cascade is central to most of the actions of LPA and it 
now remains to be show whether this is the case in its ability to induce the 
differentiation of P19 cells into cardiomyocytes.  
 
Other than PI3K/Akt, LPA may mediate effects by the activation of downstream 
signalling pathways involving PI3K/Akt/PKB coupled to Wnt/GSK-3 (Fang et al., 2002). 
The latter is also critical for differentiation of stem cells into different lineages and it 
has been reported that Wnt/-catenin signalling is crucial in DMSO induced 
differentiation of P19CL6 cells (Nakamura et al., 2003). Thus a selective inhibitor for 
Akt, Akt inhibitor XIII isoenzyme-selective Akti-1/2 which has an  IC50 for Akt1, Akt2, 
Akt3 are 58 nM, 210 nM, 2.12 µM respectively was used for our study.  In these 
studies, Akt inhibitor XIII isoenzyme-selective Akti-1/2 at a low concentration of 1M 
completely abolish expression of MLC-1v. Thus, the fact that the differentiation of P19 
cells could be abolished in our studies with concentrations of the inhibitor as low as 1 
µM suggested that Akt may be the most likely candidates that mediate the effects of 
LPA in our studies. Previous reports have indicated the involvement of Akt signalling in 
LPA and other phospholipid like sphingosine-1-phosphate mediated effects (Chen et 
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al., 2008). 
 
The other signalling pathway investigated involves that mediated by PKC. Previous 
reports have suggested that a raised activity of PKC induces erythropoietin stimulated 
erythroid differentiation and PKC plays an important role in the self-renewal and 
lineage commitment of ESC (Myklebust et al., 2000). Furthermore, DMSO triggered 
differentiation of erythroleukemia cells is associated with high expression and 
phosphorylation of PKC , ,  and   (Marchisio et al., 2005). All these findings 
suggest the importance of PKC and led us to investigate PKC in our studies. A range 
of concentrations of bisindolylmaleimide I (BIM-I) from 1-10M were selected for 
the studies (Toullec et al., 1991). This compound is a potent competitive inhibitor that 
competes for the ATP binding site in the PKC protein. It was observed that BIM-1 at 
10M completely abolish the expression of MLC at a nontoxic concentration. The 
results are consistent with PKC also being critical for the differentiation of P19 cells 
into a cardiac lineage since the latter was significantly inhibited. PKC is stimulated by 
an increase in intracellular DAG or Ca2+, which is triggered by phospholipases. 
Activated Wnt/Ca2+ increases intracellular calcium and activates PKC. In addition, 
Wnt/β-catenin signalling play a key role in DMSO induced cardiomyocytes formation 
from P19CL6 cells (Nakamura et al., 2003). Activated PKC further hampers GSK-3 
there by leading to cytosolic accumulation of  -catenin. In the interim, lithium, which 
mimics Wnt/ -catenin signalling, has been shown to activate the accumulation of  -
catenin there by inhibiting the GSK-3 phosphorylation (Hedgepeth et al., 1997; Klein 
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et al., 1996). Collectively from above studies we presume that LPA induced 
differentiation to cardiomyocytes is mediated through multi-signalling molecules which 
involves PI3K/Akt and PKC pathways. This is possibly due to the expression and 
activities of Gq coupled receptors. However, the mechanism illustrated above has to 
be validated in order to confirm the role of wnt/catenin signalling. 
 
In addition to the above signalling kinases, MAPKs have been reported to be involved in 
the differentiation of a variety of cells including stem cells (Gaur et al. 2010). However, 
previous reports have indicated that differentiation could be accelerated either by 
activation or inhibition of these MAPK families (Gaur et al. 2010; Li et al., 2002). 
 
Mitogen activated protein kinases are serine/threonine protein kinases which are 
involved in cellular processes including cell proliferation, cell survival, apoptosis, 
cellular differentiation process (Bokui et al., 2008; Chen et al., 2008; Zhang et al., 
2002). MAPKs are activated by sequential phosphorylation of MAP Kinase Kinase 
Kinase, MAP Kinase Kinase.  MAPK signalling is involved in the activation of pathways 
by numerous stimuli such as stress, growth factors, cytokines (Moriuchi et al., 2001; 
Niisato et al., 2007; Park et al., 2009). Inactivation of MAPK is achieved by the 
dephosphorylation by a MAPK phosphatase (MKPs) (Theodosiou et al., 2002). The 
MAPKs family include extracellular signal regulated kinases (ERK), p38 MAPK, and c-
Jun N-terminal kinase (JNK). P38 MAPK is mainly present in cytoplasm and nucleus of 
a cell and is moved to the nucleus following activation (Raingeaud et al., 1995). It plays 
a crucial role in normal chemotaxis, cell migration, apoptosis and differentiation (Fang 
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et al., 2000; Lee et al., 2008). p38 MAPKs are activated by G protein activated 
MAPKKK which in turn activated MAPK through an intermediate MAPKK (MEK3/6). p38 
exists in four isoforms namely alpha, beta, gamma and delta. It has been reported 
that MEK6 phosphorylates all isoforms of p38 MAPK, wherea s alpha and beta 
isoforms of p38MAPK are phosphorylated by MEK3 (Enslen et al., 2000) and this 
further phosphorylates numerous targets like transcription factors, phospholipase A2, 
and Tau protein (microtubule associated protein) (Kyriakis, 2000; Yang et al., 1999). 
 
ERK signalling is mainly involved in cellular responses like migration, proliferation, 
apoptosis and differentiation (Du et al., 2010; Liu et al., 2009; Sarbassov et al., 1997). 
Stimuli such as cytokines, stress, and growth factors activates the small GTP- binding 
protein called Ras, which can translocate and phosphorylate c-Raf proteins to the 
membrane (Beier et al., 1999). The activated Raf phosphorylates ERK1/2 through 
MAPKK (MEK1 and 2). Further, this activates ERK 1/2 and subsequently activates 
kinases like ribosomal S6 kinases (RSKs), MAPK/SAPK-activated kinase (MSK) 
and MAPK signal-activating kinase 1 (MNK1). ERK1/2 also targets on transcription 
factors like c- Myc, STAT3, Elk-1, c-Fos.  
 
The c-Jun N-terminal kinase/stress-activated protein kinases (JNK) are mainly involved 
in the cellular functions like proliferation, and apoptosis (Kostadinova et al., 2012; Xia 
et al., 1995). These signals are mediated by growth factors, cytokines and stress 
related responses (e.g. UV radiation and heat). These activates small GTP binding 
protein like Ras, Rac and also Cdc42 which then phosphorylates MAPKKKs, MAPKK 
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specifically MKK4 and MKK7. Further, it phosphorylates and activates JNK, which lead 
to the stimulation of downstream targets like c-Jun, HSF1, ELK1, p53, transcription 
factors including STAT3 and NF-kappa B. 
 
It has been reported in various cell types that LPA mediated activities like migration, 
proliferation and differentiation (as in the case of VSMCs) are mediated through p38 
and ERK1/2 (Gschwind et al., 2002; Tangkijvanich et al., 2003). LPA has also been 
involved in the activation of c-fos, which may be mediated by the ERK1/2 following 
mitogen, and stress activated kinases (MSKs) activation (Schuck et al., 2003). Hence, 
our studies were extended to examine the involvement of MAPK specifically looking at 
the p38 and ERK pathways, which are both downstream to PI3K pathway. 
 
To determine the role of ERK1/2, we used a potent inhibitor PD98059 and selective 
inhibitor of ERK1/2 that bind to the MEK1 (inactive form) and prevent the activation of 
ERK1/2. The results obtained showed that PD98059 completely abolishing MLC-1v 
expression induced by LPA at 5M concentration. This observation supports reports 
that ERKs are a principal signalling pathway in the differentiation of stem cells to 
various lineages (Jaiswal et al., 2000). ERK1/2 activation is crucial for the 
differentiation for different types of stem cells such as the stimulation of embryonic 
stem cells to neuronal cells (Li et al 2006), and also the differentiation of MSCs to 
chondrocytes (Lee et al., 2004). ERK1/2 have also been shown to play a definite role 
in mesoderm development (Kunath et al., 2007). The activation of ERK signalling 
supports differentiation through the activin/smad 2, 3 by the inhibition of 
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GSK3 and further activates the targets of Wnt such as -catenin (Singh et al. 
2012). ERK1/2 signalling also plays an important role in other LPA mediated effects 
including migration of breast cancer cells, cell proliferation as in the case with 
human bladder smooth muscle cells (Dixon et al., 1999; Stahle et al., 2003). It has 
been reported that LPA protects MSCs against hypoxia or serum deprived induced 
apoptosis through ERK signalling (Chen et al., 2008). Thus, our study showing the 
involvement of ERK1/2 signalling in the LPA induced differentiation of cardiomyocytes 
is in agreement with some of the findings above but provides the first report that this 
pathway mediates LPA-induced differentiation of P19 cells into cardiomyocytes. 
 
In contrast to the ERKs, inhibition of the p38 MAPKs pathway using SB203580 failed to 
cause any statistically significant change in LPA-induced MLC-1v expression but 
appear to enhance the latter at 10 M, a concentration that has been widely used in 
other studies (Barancik et al., 2001; Kim et al., 2009). This shows selectivity in the 
actions of the MAPKs and indicates that for P19 cells, differentiation into 
cardiomyocytes could be inhibited by blocking the ERKs but enhanced by inhibiting the 
p38 MAPK pathway.  
 
P38 MAPK signalling has been reported to be involve in many biological activities 
mediated through LPA and related compound like sphingosine-1-phosphate (Li et al.; 
Zhou et al., 2009). The role of the p38 MAPK in normal immune responses, 
chemotaxis, proliferation, apoptosis and differentiation has also been well documented 
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(Bokui et al., 2008; Ohashi et al., 2000; Zetser et al., 1999; Zhang et al., 2002). In 
addition, activation of p38 has been implicated in the induction of hESCs 
differentiation to cardiomyocytes (Matsuura et al., 2009; Xu et al., 2008) but at least 
one report has suggested that inhibition of p38 MAPK in the same cells stimulates their 
differentiation into cardiomyocytes (Gaur et al. 2010). This latter finding is consistent 
with our observations of enhanced MLC-1v expression following treatment of P19 cells 
with SB203580 even though this effect was not found to be statistically significant in our 
studies. SB203580 has been reported to inhibit specifically the  and p38 MAPK 
isoforms. The fact that this compound enhanced MLC-1v expression, albeit marginally, 
suggest that in P19 cells, enhanced differentiation might be mediated through p38 
and  Further studies, for instance transfecting specific p38 isoforms into P19 cells or 
using specific inhibitors of  and  that have recently been made commercially available 
may be worth doing. Additionally, n value of the experiments could be enhanced to 
show statistical significance of the trends currently observed. 
 
Rho associated coiled-coil forming protein kinase (ROCK or ROK) belongs to the 
serine-threonine kinase family, and is composed of ROCK-1 and ROCK-2 in 
mammals and have an amino-terminal and significantly different carboxy-terminal 
domain (Nakagawa et al., 1996; Riento et al., 2003). RhoA GTPase which is the main 
upstream target of ROCK binds to the coiled-coil region of ROCK and stimulates the 
catalytic action (Bishop et al., 2000). Stimulated ROCK is reported to be involved in 
actin myosin contraction and stress formation by increased myosin light chain 
phosphorylation, retraction of neurite and Schwann cells, cytokinesis, mitosis and 
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induced neurite formation on inhibition with Y-27632 (Hirose et al., 1998). LPA has 
been reported to cause retraction of neurites and Shwann cells through LPA receptors 
(Fukushima et al., 1998; Ishii et al., 2000). Cell differentiation may also be regulated 
by ROCK which has been shown to participate in the maturation and differentiation of 
skeletal muscles (Pelosi et al., 2007). There is however very little evidence showing 
the involvement of ROCK in the differentiation of stem cells. It has been reported that 
the ROCK pathway helps ES cells to remain as undifferentiated cells and inhibit their 
neural differentiation caused by high seeding density (Chang et al. 2010). Previous 
studies have indicated a role for ROCK in cell differentiation as mentioned in the 
introduction section. This pathway is also essential for myogenesis and 
differentiation of keratinocytes (Castellani et al., 2006; McMullan et al., 2003). In bone 
marrow-derived mesenchymal stem cells (BM-MSC) the ROCK pathway has been 
shown to induce differentiation and to potentiate the transdifferentiation of the cells 
(Pacary et al., 2007). However, ROCK has been shown to be involved in the 
inhibitory action of LPA in the neuronal differentiation from neuronalprogenitor cells 
derived from hESC (Dottori et al., 2008).  
 
We examined the effect of ROCK in the LPA induced differentiation of P19 cells into 
cardiomyocytes using the ROCK specific inhibitor Y27632. Our data suggested that the 
pre-treatment of P19 cells with a ROCK inhibitor at the EB formation stage completely 
blocked the expression of MLC-1v and thus differentiation. This strongly suggests that 
activation of the ROCK pathway may also be crucial for LPA induced differentiation. 
These effects were seen with concentrations of the inhibitor which have been 
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widely used in other studies (Chang et al. 2010; Dottori et al., 2008). Interestingly, in 
addition to the inhibitory action of Y27632 on the LPA induced differentiation, Y27632 
(5M and 10M) by itself showed some induction of differentiation of P19 cells into 
cardiomyocytes. This is similar to observations in a recent report which demonstrated 
the differentiation of human adipose tissue-derived stem cells (hADSCs) could be 
induced in a dose dependent manner following treatment with Y27632. 
 
Most of the biological effects are produced by means of crosstalk between various 
signalling cascades. Therefore, to identify the sequence of the signalling cascades, 
studies were conducted on the phosphorylation of selected proteins. The key pathways 
that participate in the differentiation of stem cells into cardiomyocytes are MAPKs and 
PI3K/Akt(PKB) pathways, however the sequence of these signalling mechanisms vary 
depending on various factors such as the type of cells and inducers used. 
Consequently, it is essential to identify the signalling cascade that facilitates LPA 
induced differentiation in P19 cells.  
 
Akt activation is mediated by PDK1 and PDK2 successively phosphorylating at 
threonine 308 and serine 473 respectively (Alessi et al., 1996; Alessi et al., 1997). 
PI3K/Akt plays a key role in cellular proliferation and survival that are mediated through 
downstream effectors like Wnt signalling and nuclear factor Kappa-B (NF-B). In 
addition, it is shown to inhibit Glycogen Synthase Kinase-3 (GSK-3 a negative 
regulator of Wnt pathway. Akt plays multiple roles in maintaining the vital functions of 
cardiomyocytes. Over expression of Akt has also been shown to induce the expression 
181   
of vascular endothelial growth factor and angiopoitin-2 thus regulating myocardial 
capillary growth (Mora et al., 2003; Shiojima et al., 2005). Most importantly, during 
cardiomyocytes differentiation it stimulates cardiomyocytes cells, and cardiac 
progenitor cells proliferation/survival (Beltrami et al., 2003; Gude et al., 2006). 
Furthermore, Akt has been shown to play a crucial role in LPA mediated effects in 
cellular systems. The cell survival in ovarian cancer cells by LPA and anti-apoptosis 
mediated by C. difficile toxin via LPA are mediating through Akt activation. Thus to 
extend our studies on Akt, experiments were carried out to look at the phosphorylation 
of Akt at serine 473. The data obtained showed that Akt was phosphorylated by 5M 
LPA, starting from 5 minutes. The peak of activation was found at a time point of 15 
minutes, and was sustained until 30 minutes, declining thereafter. However, studies 
conducted to look at the involvement of the LPAR1/3 and LPAR4 receptors, with 
Ki16425 and suramin revealed no changes to the LPA induced activation of Akt at Ser-
473. In addition, selective signalling molecule inhibitors of p38 MAPK (SB203580 
10M), ERK1/2 (PD95080 5M), PI3K (LY294002 5M), PKC (BIM 10M), and 
ROCK (Y27632 10M) caused no significant change in the expression and activation 
of Akt at Ser-473 residue. These data suggest that the phosphorylation/activation of 
Akt at least on Ser-473 may not be directly regulated by the pathways highlighted 
above. However, Akt inhibitor XIII that selectively inhibits the activity of Akt1/Akt2 
completely abolished the expression of MLC-1v strongly suggesting a role for Akt in 
the differentiation process. 
 
Reports have suggested induction of differentiation of H9C2 cells into cardiomyocytes 
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with lithium, an inducer of Wnt signalling and inhibitor of glycogen synthase kinase-
3. The above study has shown the differentiation was achieved through PI3K 
signalling however, was independent to Akt pathway (Kashour et al., 2003). 
Comparable to our studies, it might be that differentiation of P19 cells into 
cardiomyocytes is mediated through PI3K but in an Akt-Ser473 independent manner. 
The activation of Akt occurs via phosphoinositide-dependent kinase1 (PDK1) which 
phosphorylates T-308 and subsequently auto phosphorylates or by the action of 
PDK2 which phosphorylates Ser-473. In addition, Ser-473 phosphorylation could also 
be achieved through mammalian target of rapamycin complex 2 (mTORC2). 
LY294002, a selective inhibitor of PI3K, acts at the ATP binding site of the protein. 
Akt inhibitor XIII is a selective inhibitor of Akt which acts on plecktrin homology (PH) 
domain and inhibits activity of Akt1/Akt2. Our data from the inhibitory studies have 
showed that PI3K and Akt completely blocked the expression of the cardiac marker 
MLC-1v; however, neither PI3K nor Akt inhibitors could inhibit LPA induced activation 
of Akt at the Ser-473 residue. Thus, Akt and PI3K may be signalling independently in 
P19 cells with regards to LPA induced differentiation.    
 
LPA has been shown to induce the proliferation of pre-adipocytes, which was 
mediated by dual pathways. The report indicated that the one mediated through 
GPCR was through PTX-insensitive mechanism in association with PI3K but Akt 
independent (Holmstrom et al., 2010). Interestingly, Akt activation at Thr-308 and Ser-
473 additionally occurs by the signalling molecule IKBKE, known as IKK (atypical IB 
kinase ) and IKKi. This report suggests that the phosphorylation via PDK1and PDK2 is 
183   
dependent on the pleckstrin homology (PH) domain, which normally occurs either 
through PI3K or by the mammalian target of rapamycin complex 2 (mTORC2) (Guo et 
al., 2011). In addition, there are similar reports that prove the activation of Akt through 
atypical IB kinase  and TANK-binding kinase 1 (IKK/TBK1) (Xie et al., 2011). In both 
these scenario, it is observed that the activity of Akt is PI3K independent. Hence, in LPA 
induced differentiation of P19 cells, the activation of Akt may occur through a PI3K 
independent pathway.  
 
PI3K/Akt signalling has many downstream binding effectors including Raf1, SMAD3 
and reports suggest evidence of cross talk between the PI3K and MEK pathways 
(Conery et al., 2004; Remy et al., 2004; Reusch et al., 2001; Runyan et al., 2004). 
Experiments conducted with SB203580, a potent P38 inhibitor, did not however show 
any profound effect on LPA-induced differentiation of P19 cells, indicating that this 
kinase may either not be involved in mediating the effects of LPA or may not be fully 
activated by the latter. Thus to confirm whether P38 is in fact activated in these cells 
further studies were carried out examining the its phosphorylation in response to 5M 
LPA. The results show clearly that p38 MAPK was activated in response to LPA and 
this was observed from 5 minutes, peaking at 10 minutes but declining after 30 
minutes. Further to the above experiment, studies were conducted to look at the effect 
of inhibitors of LPA receptors and signalling molecules on the activation of p38 
MAPK. Our data indicated that the p38 MAPK activation was completely abolished by 
LPA1/3 and LPA4 receptor antagonists, Ki16425 (10 M) and suramin (0.05mg/ml). 
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Therefore, it proves the involvement of LPA1/3 and LPA4 receptors in the activation of 
p38 MAPK. In addition, LY294002 5 M and Y27632 10 M abolished the LPA induced 
activation of p38 MAPK while SB203580, BIM, Akt inhibitor XIII and PD95080 caused 
no significant changes to the phosphorylation of p38 MAPK. Hence, this suggests that 
the PI3K and ROCK signalling pathways through downstream targets MEK3/6 could be 
inducing the activation of p38 MAPK. This in turn may act to regulate MLC1v 
expression but only marginally. 
 
ERKs are generally activated by ligands that bind to G protein coupled receptors, 
cytokines, growth factors, carcinogens. The two forms of ERKs, ERK1 and ERK2, are 
activated through G and G The main effectors linked to these G proteins are PI3K 
and PKC. The activated PKC promote the activation of Ras, Raf and the MEK 
pathways (Ginnan et al., 2006; Osmond et al., 2005). MEK1 and 2 are phosphorylated 
by activated c-Ras and it in turn further phosphorylates and activates the downstream 
targets, ERK1 and ERK2 (Burgering et al.,1995). Studies conducted with 5M LPA 
showed that it could phosphorylate and activate ERK1/2 at 3 minutes but declined after 
5 minutes. This activation was completely abolished by LPAR1/3 and LPAR4 receptor 
antagonists, Ki16425 and suramin. This again demonstrates the involvement of 
LPAR1/3 and LPAR4 receptors in the activation of ERK1/2. In addition, all the 
signalling inhibitors mentioned above for PI3K, PKC, ROCK, Akt and ERK1/2 showed 
complete inhibition of activation of phospho-p42/42. SB203580 was without effect. 
Hence, it is very clear that ERK1/2 plays a central role in the differentiation process of 
P19 stem cells into cardiomyocytes induced by LPA and may be the point of 
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convergence of multiple signalling events originating from LPAR1/3 and 4 receptors. 
The only signalling event that could occur through G12/13 is the Rho/ROCK pathway 
and our data has shown that ROCK completely abolished the activation of ERK1/2 
induced by 5M LPA. The implication of ROCK is consistent with a previous study 
showing that LPA mediated activation of Na/H exchangere3 through the LPA5 receptor 
was mediated via ROCK/MEK/ERK pathway in intestinal epithelial cells (Yoo et al., 
2011). ROCK via G12/13 has also been shown to abolish the activation of ERK. It is 
interesting to note that the ROCK pathway has been indicated to mediate cardiac 
myocyte hypertrophy mediated through the activation of p-ERK/GATA-4 (Yanazume et 
al., 2002). Similarly, in glioblastoma cell migration and proliferation, ROCK plays a 
crucial role signalling the events through ERK activation (Zohrabian et al., 2009). 
 
PD98059 an ERK1/2 inhibitor abolished the activation of p-ERK induced by 5M LPA. 
PD98059 is a selective inhibitor of p42/44 MAPK that bind to the MEK1 (inactive) and 
prevent the activation of ERK1/2. This could logically explain its inhibitory action on 
ERK1/2 phosphorylation. As already stated, inhibitors for PI3K, PKC, and Akt also 
blocked ERK1/2 activation suggesting cross talk between these pathways. It is likely 
however that signalling through PI3K and PKC may be distinct from Akt since inhibition 
of PI3K did not block Akt phosphorylation. A distinct role for Akt is consistent with a 
previous report in which glycogen-like peptide 2 (GLP2) stimulated the differentiation 
to neuronal cells via Akt/mTOR/ERK1/2 and was confirmed by the expression of 
vasoactive intestinal polypeptide (VIP) (de Heuvel et al., 2010). Similarly, LPA could 
induce differentiation of P19 cells into cardiomyocytes, through Akt/mTOR/ERK1/2 
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pathway. In contrast, PI3K/PKC could signal through Ras/B-Raf/ERK linked to 
G(Hawes et al., 1996).
 
In addition to the action of G, Gq can stimulate PLC and PKC, which can further 
activate the MEK and ERK pathways. In nerve growth factor induced differentiation of 
PC12 cells, it was observed that this was mediated through the activation of atypical 
PKC through Src or Ras or PI3K mediated pathways. The activated PKC lead to the 
induction of IKK and resulted in regulating the activation of NF-B. In addition, MEKs 
are downstream targets of PKC and in this study; the induction of differentiation was 
mediated through the involvement of MAPKs (Wooten et al., 2000).  
 
The close links between PI3K and PKC are well demonstrated in vasculogenesis which 
is also dependent on the p110 and p1110 subunits of PI3K that interacts with the 
downstream targets of PKC catalytic subunits, /andPKCin mouse ES cells 
(Bekhite et al., 2011). Similarly, in IGF-I induced HL60 cells differentiation into 
macrophages the signalling events are reported to be through PI3K/PKC(Liu et al., 
1998) 
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Chapter 5 
Summary and conclusions 
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The objective of this thesis was to establish the effect of LPA in the differentiation of 
P19 stem cells into cardiomyocytes and to investigate the signalling mechanisms 
involved. The data obtained confirm that LPA can induce P19 stem cells to differentiate 
into cardiomyocytes and exerts this effect at known physiological concentrations, which 
can exist in vivo. In addition, the effects are linked to well characterised LPA receptors 
(LPAR1/3 and 4) which are in turn coupled to downstream signalling pathways of which 
those involving the ROCK, PI3K, PKC and/or Akt may be critical, and may converge on 
ERK1/2. Inhibition of any of these pathways has the potential to suppress differentiation. 
In contrast, signalling leading to P38 activation may potentially suppress the process but 
this needs further clarification. Cross inhibition studies revealed a complex network of 
cross talk between the pathways identified and this is summarised in Figure 49 below 
for clarification. 
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Future Work 
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The outcome from this thesis has generated further interesting areas that needs to be 
addressed and these are summarised below.  
1. Our studies have confirmed the involvement of LPA1/3/4 receptors in the induction 
of differentiation with pharmacological inhibitors. However, we could not 
investigate the role of LPAR2 because of a lack of commercially available inhibitor 
for this receptor subtype. It is however important to establish this especially as 
PCR analysis of receptor expression profile showed that LPAR2 mRNA increased 
2.5 fold when cells where treated with 5M LPA. In the absence of 
pharmacological inhibitors, the studies could be performed using siRNA 
transfection to deplete LPAR2. . 
2. Studies involving Akt seem to suggest that this pathway may be activated 
independently of PI3K. Thus, experiments should be carried out to determine the 
PI3K independent activation of Akt. 
3. This thesis has uncovered the role of the MAPKs p38 MAPK and ERK but did not 
investigate JNK. The latter is a critical member of the MAPKs, which could 
regulate differentiation through AP1 signalling. 
4. In addition to AP-1, further studies could be carried out to investigate the role of 
other transcription factors including those specific to a cardiac lineage 
commitment. 
5. The data generated for the p38 MAPK suggest only a marginal role. This is an 
interesting observation which needs further investigation. In the first instance, it 
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would be important to confirm the current trends by increasing the n value to 
improve on statistical significance. Following this, it would be important to confirm 
whether LPA activates all different isoforms of P38 and whether these mediate 
different effects. This suggestion is based on the fact that SB203580 selectively 
blocks the  and  isoforms and we therefore currently have no data to suggest 
whether  and  isoforms play any role in mediating the effects of LPA or indeed 
whether the effects may be different to those seen with  and . These studies 
could be carried out using transfection of cDNA to over express each isoform and 
determine whether this alters MLC-1v expression. Additionally siRNA could be 
exploited to deplete each isoform but prior to this it would be essential to 
demonstrate whether P19 cells express all 4 isoforms of P38 using western 
blotting. 
6. Suramin, an LPAR4 non-selective antagonist at very low concentration  showed 
induction of differentiation in the absence of LPA. This was also true for other 
inhibitors used even though they each blocked LPA induced differentiation. It 
would be worth investigating these unexpected effects and establish the cellular 
mechanisms associated with each drug.   
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Appendix 1. Cell Line 
 
P19 Embryonal Carcinoma Stem Cell Line 
Cell Line Name P19  
 
Species Mouse 
Cell Line 
Description 
The P19 cell line was derived from an embryonal carcinoma induced in 
a C3H/He strain mouse. The pluripotent P19 cells can be induced to 
differentiate into neuronal and glial cells in the presence of retinoic 
acid. Aggregates of P19 cells differentiate into cardiac and skeletal 
muscle in the presence of dimethyl sulfoxide (DMSO).  
Tissue Embry 
Growth Mode Adherent 
Culture 
Medium 
 
Alpha MEM + 2mM Glutamine + 10 % FBS 
Subculture 
Routine 
Split cells at 70-80% confluency using trypsin/EDTA. 
Suppilier European Collection of Cell Cultures (ECACC) 
http://www.hpacultures.org.uk/collections/ecacc.jsp 
Catelogue 
Number 
95102107 
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Appendix 2. Cell culture reagents 
 
REAGENTS DESCRIPTION SUPPLIER STORAGE 
Minimal Essential 
Medium (MEM) 
Alpha Medium (α- 
MEM, no 
nucleosides 
Contains non-
essential amino 
acids, sodium 
pyruvate, lipoic 
acid, B12, biotin, 
and ascorbic 
Invitrogen, UK 
http://www.invitrogen.com 
(Product code:22561021) 
Fridge 4°C 
Foetal Bovine 
Serum 
Heat inactivated Invitrogen, UK 
http://www.invitrogen.com 
(Product code:10500064) 
Stock: -20°C 
Penicillin-
Streptomycin 
(10,000 U/ml) 
Contains 10,000 
units/ ml of 
penicillin and 
10,000 µg/ ml of 
streptomycin.   
Prevent bacterial 
contamination of 
cell cultures due to 
their effective 
combined action 
against gram-
positive and gram-
negative bacteria. 
Invitrogen, UK 
http://www.invitrogen.com 
(Product code: 15140122) 
Stock: -20°C 
0.5% Trypsin-
EDTA (10X)-no 
phenol red 
Contains 5.0 g/L 
of trypsin, 2.0 g/L 
of EDTA.4Na, 8.5 
g/L of NaCl. 
Invitrogen, UK 
http://www.invitrogen.com 
(Product code: 15400054) 
Stock: -20°C 
Diluted aliquots 
of stock 
Solution: Fridge 
4°C, 
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Appendix 3. Oleoyl-L-α-lysophosphatidic acid sodium salt 
 
Synonym 1-Oleoyl-sn-glycerol 3-phosphate sodium 
salt, 3-sn-Lysophosphatidic acid, 1-oleoyl 
sodium salt, LPA sodium salt 
Description Endogenous agonist for LPA1 and LPA2 
receptors. LPA does not induce 
angiogenesis, but has effects on 
endothelial cell physiology that are similar 
to those of sphingosine 1-phosphate. 
Induces cell migration of cancer and non-
cancer cells. 
Empirical Formula  
 
C21H41O7P 
CAS Number  
 
22556-62-3  
 
Solubility Solution has been achieved  in 1% 
phosphate buffered saline (PBS), pH 
7.2containing 0.1% Fatty acids free BSA 
Storage −20°C 
Molecular Weight 436.5 
Stock concentration 5mM 
Supplier Sigma (Sigma-Aldrich), UK 
http://www.sigmaaldrich.com 
Catalogue number L7260 
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Appendix 4. Monoclonal Anti-Cardiac Myosin Light Chain I Antibody 
 
Antibody Name Anti-Myosin light chain 3 antibody 
[MLM527] 
Antibody Type Primary antibodies 
Description Mouse monoclonal [MLM527] to Cardiac 
Myosin light chain 
Immunogen Human ventricle myosin light chain I 
Specificity Antibody reacts with ventricle myosin light 
chain I (MLC-1v) 
Band size Predicted band size : 22 kDa 
Observed band size : 25 kDa 
Storage Aliquot and store at -20°C or -80° 
Dilution used 1:500 in blocking buffer 
Secondary antibody 
Required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Abcam, UK 
http://www.abcam.com 
Catalogue number ab680 
 
233   
Appendix 5. Mouse Phospho-Akt (Ser473) (587F11) monoclonal antibody 
 
Antibody Name Mouse Phospho-Akt (Ser473) (587F11) monoclonal 
antibody 
Antibody Type Primary antibody 
Description Mouse monoclonal antibody to Akt phosphorylated at 
serine 
473 (Ser473) 
Immunogen Synthetic phospho-peptide (KLH-coupled) corresponding to 
residues around Ser47 of mouse Akt. 
Specificity Phospho-Akt (Ser473) (587F11) Mouse mAb detects 
endogenous levels of Akt only when phosphorylated at 
serine 473. This antibody does not detect Akt 
phosphorylated at other sites or related kinases such as 
PKC and p70 S6 kinase. 
Band size 60 kDa 
Storage Store at –20°C. Do not aliquot the antibody. 
Dilution used 1:1000in blocking buffer 
Secondary antibody 
Required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Cell Signallng Technology 
http://www.cellsignal.com 
Catalogue number 4051 
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Appendix 6. Phospho-p38 MAPK (Thr180/Tyr182) (28B10) Mouse mAb 
 
Antibody Name Phospho-p38 MAPK 
(Thr180/Tyr182) (28B10) Mouse mAb 
Antibody Type Primary antibody 
Description Mouse monoclonal antibody to p38 MAP kinase (MAPK) 
phosphorylation at Thr180 and Tyr182. 
Immunogen Monoclonal antibody is produced by immunizing animals with a 
synthetic phosphopeptide corresponding to residues around 
Thr180/Tyr182 of human p38 MAPK. 
Specificity Phospho-p38 MAPK (Thr180/Tyr182) (28B10) Mouse mAb 
detects p38 MAPK only when activated by dual phosphorylation 
at Thr180 and Tyr182. This antibody does not significantly cross-
react with the corresponding phosphorylated forms of either 
p44/42 MAPK (Erk1/2) or SAPK/JNK. It does not detect 
nonphosphorylated p38 MAPK. 
Band size 43 kDa 
Storage Store at –20°C. Do not aliquot the antibody. 
Dilution used 1:2000in blocking buffer 
Secondary antibody 
Required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Cell Signallng Technology 
http://www.cellsignal.com 
Catalogue number 9216 
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Appendix 7. Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb 
 
Antibody Name Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse 
mAb 
Antibody Type Primary antibody 
Description Mouse monoclonal antibody to p38 MAP kinase (MAPK) 
phosphorylation at Thr180 and Tyr182. 
 
Immunogen Monoclonal antibody is produced by immunizing animals with a 
synthetic phosphopeptide corresponding to residues 
surrounding Thr202/Tyr204 of human p44 MAP kinase. 
Specificity Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse 
mAb detects endogenous levels of p44 and p42 MAP Kinase 
(Erk1 and Erk2) when dually phosphorylated at Thr202 and 
Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly 
phosphorylated at Tyr204. This antibody does not cross-react 
with the corresponding phosphorylated residues of either 
SAPK/JNK or p38 MAP kinase. 
Band size 42, 44 kDa 
Storage Store at –20°C. Do not aliquot the antibody. 
Dilution used 1:2000in blocking buffer 
Secondary antibody 
required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Cell Signallng Technology 
http://www.cellsignal.com 
Catalogue number 9106 
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Appendix 8. Monoclonal Anti-β-Actin antibody conjugated to horseradish 
peroxidise (HRP) 
Antibody Name Monoclonal Anti-β-Actin antibody conjugated to 
horseradish peroxidise (HRP) 
Antibody Type Primary antibody, isotype IgG1 
Description A purified fraction of mouse monoclonal anti-b-actin 
isolated from ascites fluid of the AC-15 and conjugated 
horseradish peroxidise (HRP) 
Immunogen slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-
Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, 
conjugated to KLH. 
Specificity Antibody reacts specifically with β-actin found many tissues 
and species 
Band size 42 kDa 
Storage Aliquot stored at -20°C or -80°C 
Dilution used 1:10000 in blocking buffer 
Secondary antibody 
Required 
Not required 
Supplier Sigma (Sigma-Aldrich), UK 
http://www.sigmaaldrich.com 
Catelogue numebr A3854 
Description Suramin is a polysulfonated naphthylurea anticancer agent that 
inhibits tumor cell proliferation. It uncouples G-proteins from 
receptors. It is an broad spectrum antagonist at P2X and P2Y 
purinergic receptors. 
Empirical Formula  C51H34N6Na6O23S6 
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Appendix 9. Suramin 
 
Description Suramin is a polysulfonated naphthylurea anticancer agent that 
inhibits tumor cell proliferation. It uncouples G-proteins from 
receptors. It is an broad spectrum antagonist at P2X and P2Y 
purinergic receptors. 
Empirical Formula  C51H34N6Na6O23S6 
CAS Number  129-46-4 
Solubility H2O: >10 mg/ml 
Storage Store at room temperature protected from light.  
Molecular Weight 1429.17  
Stock concentration 0.5mg/ml 
Supplier Sigma (Sigma-Aldrich), UK 
http://www.sigmaaldrich.com 
Catalogue number S 2671 
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Appendix 10. SB203580 
 
Synonym 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- 
pyridyl)1H-imidazole 
Description A highly specific, cell-permeable inhibitor of p38 kinase 
(IC50 = 34 nM in vitro, 600 nM in cells). 
Empirical Formula  C21H16N3OSF 
CAS Number  152121-47-6 
solubility DMSO 
Storage Protect from light 
Solid: -20°C 
Stock solution Aliquots: -20°C 
Molecular Weight 377.4 
Stock concentration 10mM (1mg/265μl of DMSO) 
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue number 559389 
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Appendix 11. LY294002 
 
Synonym 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one  
Description A phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor that 
acts on the ATP-binding site of the enzyme 
Empirical Formula  C19H17NO3 
CAS Number  154447-36-6  
Solubility DMSO 
Storage Protect from light 
Solid: -20°C 
Stock solution Aliquots: -20°C 
Molecular Weight 307.4 
Stock concentration 20mM  
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue number 440202 
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Appendix 12. Bisindolylmaleimide I 
 
Synonym 2-[1-(3-Dimethylaminopropyl)-1Hindol- 3-yl]-3-(1H-indol-3-yl)-
maleimide 
Description A reversible protein kinase C (PKC) inhibitor that acts as a 
competitive inhibitor for the ATP-binding site 
Empirical Formula  C25H24N4O2 
CAS Number  133052-90-1 
Solubility DMSO 
Storage Protect from light 
Solid: -20°C 
Stock solution Aliquots: -20°C 
Molecular Weight 412.5 
Stock concentration 2.4mM  
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue number 203290 
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Appendix 13.Y-27632 
Synonym Rho Kinase Inhibitor VI 
Description A highly potent, cell-permeable, selective inhibitor of Rho-
associated protein kinase (Ki = 140 nM for p160 
ROCK (ROCK-I). Also inhibits ROCK-II with almost equal 
potency. Inhibition is achieved by competing with 
ATP for binding to the catalytic site. 
Empirical Formula  C14H21N3O · 2HCl · H2O 
solubility 500 μg/296 μl solution of Y-27632 in H2O. 
Storage -20°C 
Protect from Light 
Molecular Weight 338.3 
Stock concentration A 5 mM (500 μg/296 μl) solution of Y-27632 in H2O. 
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue number 688001  
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Appendix 14. Pertussis Toxin 
 
Description Pertussis toxin uncouples G proteins from receptors by ADP 
ribosylating a cysteine residue near the carboxyl terminus of the 
α subunit. 
Empirical Formula  C14H21N3O · 2HCl · H2O 
solubility 50 micro gram/ 500 micro litre in  sterile, distilled water 
Storage Store, as supplied, at 2°C to 8°C. Upon reconstitution, apportion 
into working aliquots and store at 2°C to 8°C. 
Suspensions are stable at 2°C to 8°C for up to six months. DO 
NOT FREEZE. 
Molecular Weight 117 
Stock concentration 50 micro gram/ 500 micro litre in  sterile, distilled water 
Supplier Invitrogen,UK  
https://www.lifetechnologies.com 
Catalogue number PHZ1174 
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Appendix 15. Akt inhibitor VIII isoenzyme-selective Akti-1/2 
 
Synonym 1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-
yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one, Akti-1/2 
Description A cell-permeable and reversible quinoxaline compound that 
potently and selectively inhibits Akt1/Akt2 
activity (IC50 = 58 nM, 210 nM, and 2.12 μM for Akt1, Akt2, and 
Akt3, respectively, in in vitro kinase 
assays). The inhibition appears to be pleckstrin homology (PH) 
domain-dependent. 
Empirical Formula  C34H29N7O 
Solubility A 10 mM (1 mg/181 μl) solution of Akt Inhibitor VIII 
Storage +2°C to +8°C 
Molecular Weight 551.6 
Stock concentration 10 mM 
Supplier EMD Millipore 
http://www.emdmillipore.com 
Catalogue number 124018 
